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Abstract 
The elderly population is inherently more susceptible to gastrointestinal problems and diseases 
due to significant age-related gastrointestinal changes experienced in gut physiology, reactivity 
of the immune system, and/or diet. These factors, coupled with increased occurrence of disease 
and corresponding medication use, could also modify the composition of gut microbiota. The 
impact of non-steroidal anti-inflammatory drugs (NSAIDs) on the physical gastrointestinal tract 
has already been shown. However, the impact of these factors on the microbiota inhabiting the 
GI tract has not been well established.   A better understanding of the relationship between 
medication use and gut microbiota composition may have beneficial implications for general and 
elderly health. Increasing knowledge on the health benefits of probiotics among consumers has 
dramatically surged the use of probiotics in the recent decades. The objective of this study was to 
determine the impact of commonly administered medical drugs and commonly consumed 
caffeine on the viability and functionality of commercially available probiotic supplements. Ten 
probiotic supplements containing various strains of bifidobacteria (B. longum, B. bifidum, B. 
lactis, B. breve, B. infantis) and lactobacilli (L. acidophilus, L. rhamnosus, L. reuteri, L. gasseri, 
L. plantarum, L. casei, L. brevis, L. salivarius, L. paracasei) were individually grown in 
laboratory medium de Man, Rogosa and Sharpe (MRS) broth at 37°C for 24 h. Batches of 10 mL 
MRS broth were mixed with 100 µL of aspirin stock, inoculated with 1 mL overnight grown 
probiotic culture, and then incubated at 37ºC for 2h. Bacterial populations were determined at 0 
and 2h of incubation.  In addition, bile resistance, β-galactosidase activity, reducing power, and 
protein expression were examined.  Our results showed that six out of the ten commercial 
probiotic supplements contained bacterial populations as claimed on their respective labels. The 
β- galactosidase activity of each supplement was determined. The enzyme activity ranged from 1 
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to 1,120 Miller units. A single supplement was selected for continued testing in objective 2. 
Exposure to one tablet of aspirin was found to decrease bacterial population approximately 6.75 
log CFU/ml, and exposure to caffeine (0.5% w/v)  decreased population approximately 0.23 log 
CFU/ml. Determination of β- galactosidase activity resulted in reductions in enzyme activity post 
aspirin exposure and caffeine enhanced enzyme activity.  
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1 CHAPTER 1 
Introduction 
As the aging process proceeds, the elderly naturally encounter a decrease in the number 
of beneficial bacterial species present in the microbiota. The stability of gut microbiota in the 
elderly is affected by physiological changes in the gastrointestinal tract stimulated by increasing 
age. Combined with factors such as changes in lifestyle and diet, diminished performance of the 
immune system could  negatively impact  the presence of microbes (Biagi et al., 2010). Because 
natural declines in physiological function commonly occur with age, this decline may indirectly 
alter the composition of gut microflora due to the influence of absorption and/or metabolism of 
nutrients. Decreased muscle bulk, coupled with tooth loss, causes mastication, and, in some 
cases, swallowing difficulties (Karlsson, Persson, & Carlsson, 1991; Newton, Yemm, Abel, & 
Menhinick, 1993). Diminished sensory sharpness leads to increased blandness in food flavor 
(Weiffenbach, Baum, & Burghauser, 1982). The combination of these factors can result in 
nutritionally imbalanced diets in the elderly population.  
The reduction of beneficial bacteria in the gut microbiota of the elderly is often 
exacerbated by an increase in the consumption of medications consumed as a result of an 
increase in the occurrence of illnesses commonly associated with aging.  Common ailments 
suffered by the elderly are often treated with a range of medications, from non-steroidal anti-
inflammatory drugs (NSAID), to acetaminophen (Tylenol).  Individuals consuming probiotic 
products sparingly and inconsistently are not equip to withstand the potential decline in bacterial 
population. Therefore, medication use could alter their microbiota composition, and cause 
potential gastrointestinal problems and diseases. 
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In recent years, considerable effort has been made to investigate the positive impact of 
probiotics on health. Probiotics are live microorganisms administered in adequate amounts that 
confer a beneficial health effect on the host. Traditionally probiotics have been consumed via 
dairy products such as milk, cheese, and yogurt. The most commonly used probiotics in foods 
are Lactobacillus and Bifidobacterium.  For centuries, lactic acid bacteria (LAB) have been 
utilized in food fermentation, and the functions of these food fermenting agents have expanded 
to also include potential as conferrers of health benefits (Song, Ibrahim, & Hayek, 2012). Lactic 
acid bacteria are nonpathogenic, and are generally recognized as safe (GRAS). Recent studies 
have demonstrated that the effects of probiotics can potentially be further improved (Gyawali & 
Ibrahim, 2012). Plants rich in micronutrients such as manganese and zinc have been shown to 
enhance the ability of probiotics to produce organic acids. These organic acids offer potential as 
a natural antimicrobial, thus improving the safety of foods and supporting human health (S. 
Ibrahim, Dharmavaram, Seo, & Shahbazi, 2003; Nakashima, 1997). Enzymes also enhance the 
production of organic acids such as lactic and acetic acids, which act as antimicrobial agents and 
suppressors of pathogenic bacteria growth (S. Ibrahim et al., 2003; S. A. Ibrahim & Salameh, 
2001; Nakashima, 1997).   
The promotion of health via probiotic supplements, however, has not been well 
established. A broader selection of probiotic supplements to choose from benefits consumers and 
has the potential to increase the likelihood of purchase. Currently probiotics are available as 
dietary supplements in the form of capsules, tablets, powders, liquids, and chews. The elderly 
population benefit from the convenience of multiple probiotic supplements as well because the 
assortment of forms allows them to select a product that caters to their mastication or swallowing 
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abilities. Elderly with weak swallowing abilities are now able to choose a liquid or powder form 
of a probiotic supplement for increased ease of administration.  
Despite the negative impact medical drugs have on the microbiota, these medications are 
necessary in order to mitigate pain and other health problems experienced by the elderly. This 
has prompted scientists to look for alternative means to combat these negative effects and 
enhance the beneficial bacteria of the microbiota. In recent years, considerable effort has been 
made to identify dietary therapeutics for this purpose. The most practical application for elderly 
individuals to combat the negative impact of medications is to maintain a well-balanced daily 
diet that also includes probiotics each day. The first objective of this study was to examine the 
viability of probiotics in commercial dietary supplements. The second objective was to 
determine the impact of aspirin and caffeine on the functionality of a probiotic supplement. In 
this project, functionality was determined by performing β- galactosidase activity, bile resistance, 
reducing power, and protein expression.  
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2 CHAPTER 2  
Literature Review 
2.1 Aging 
2.1.1 The Current Situation 
In recent years there has been a dramatic rise in the elderly population as a result of an 
increased life expectancy that can be contributed to innovations in science and medicine (E. 
Woodmansey, 2007). However, most elderly individuals are not necessarily experiencing 
longevity, which is the potential to live a long life in a healthy state (Saunier & Doré, 2002). The 
elderly population is inherently more susceptible to gastrointestinal problems and diseases due to 
significant age-related gastrointestinal changes experienced in gut physiology, reactivity of the 
immune system, and/or diet. Studies have demonstrated the need for an emphasis on gut 
microbiota homeostasis as a means of experiencing longevity, given the importance of the 
microbiota in elderly health. Factors commonly associated with aging often lead to compromised 
microbial balance of the elderly microbiota. When dietary habits cannot support this balance, 
alternative methods, such as the consumption of probiotic products is an option for promoting 
gut microflora homeostasis.  
Aging is a significant topic of concern throughout the world. By definition, aging is the 
‗regression of physiological function accompanied by advancement of age‘ (Imahori, 1992). By 
2040, the US Census Bureau estimates that the elderly population will double from 7 percent to 
14 percent of the total world population; for the first time in history, within the next 10 years, 
there will be more people in the world aged 65 and over than children under 5 (Kinsella, 2009). 
In the state of North Carolina alone, the number of people age 65 and up has increased 25.7 
percent between 2000 and 2010; 12.9 percent of the state‘s total population. According to the 
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UNC Institute on Aging, between 2010 and 2030 North Carolina‘s elderly population will 
increase by 400,000 people per decade, reaching 2.14 million or about 18 percent of the state‘s 
total population by 2030 (Aging, 2011). In 2010the U.S. Bureau of the Census calculated 
individuals‘ 65 years and up as a percentage of total population (Fig. 2.1) in the United States. 
Increases in the elderly population correlates with increases in financial burdens caused by 
healthcare needs, treatment costs, and end of life expenses. 
 
 
 
Figure 1 The percentage of elderly individuals in 2010 by state. 
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Bacteria colonize all of the physically available space along the gastrointestinal tract, 
with varying distribution. These bacteria have invaluable functions in the human body. ―Human 
beings have been recently reviewed as ‗metaorganisms‘ as a result of a close symbiotic 
relationship with the intestinal microbiota. This assumption imposes a more holistic view of the 
aging process where dynamics of the interaction between environment, intestinal microbiota and 
host must be taken into consideration.‖ (Biagi et al., 2010) There are several genetic and 
metabolic attributes provided by gut bacteria that humans remain unable to evolve independently 
(Bäckhed, Ley, Sonnenburg, Peterson, & Gordon, 2005). The relationship between human host 
and the composition of its gut microflora is primarily mutually beneficial. The metabolic activity 
of the gut microbiota provides the human host metabolic energy and absorbable substrates and 
nutrients, while the human host provides the microbiota a source of energy and nutritious 
products for growth and development.   
An essential feature of a healthy gut microbiota is the production of short chain fatty 
acids (SCFA) such as acetate, butyrate, and propionate(Barcenilla et al., 2000; Louis & Flint, 
2009).  SCFA have a nutritious effect on the intestinal epithelium. Each of the three major short-
chain fatty acids stimulate epithelial cell proliferation and differentiation in the large and small 
intestine in vivo (Butler, Sun, Weber, Navarro, & Francis, 2000). The microbiota also ferments 
carbohydrates, which provides energy to the colon; serving 50% of the daily energy 
requirements, for colonic epithelial cells (Tuohy, Probert, Smejkal, & Gibson, 2003).This energy 
production is accomplished by fermenting butyrate, a carbohydrate, into organic acids (Tuohy et 
al., 2003).  Butyrate is active in the physical separation of the microbiota and enterocytes; as a 
result of  this separation the release of mucins, the protein component of the mucus layer that 
forms gel, is stimulated (Barcelo et al., 2000; Petersson et al., 2011).  
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Additional general health benefits conferred to the host by the gut microflora include 
immunostimulation, synthesis of vitamins, improved digestion and absorption, cholesterol 
reduction, lowered gas distension, and inhibition of potentially pathogenic bacterial growth 
(Wallace et al., 2011).  Health benefits conferred to the host are contingent upon maintaining a 
homeostatic state amongst the network of microflora.  
Common declines in health, specifically gut microbiota health, occur with aging. ―Age-
related physiological changes in the gastrointestinal tract, as well as modification in lifestyle, 
nutritional behavior, and functionality of the host immune system, inevitably affect the gut 
microbial ecosystem.‖ (Biagi et al., 2010) Increased occurrence of disease and corresponding 
medication use in the elderly also modify the composition of the gut microbiota (Tiihonen, 
Ouwehand, & Rautonen, 2010). Members of the elderly community encounter unfavorable 
changes in microbiota, which can lead to health problems. 
The microorganisms of the gastrointestinal tract are not indestructible, and the positive 
attributes provided by the bacteria can be overcome by pathogens. Some pathogens have evolved 
specifically for gastrointestinal infection, examples include Salmonella spp., Escherichia coli 
strains and Campylobacter jejuni (Tuohy et al., 2003). The balance can be delicate, and many 
age related physiological issues potentially lead to harmful effects caused by the gut microflora; 
examples include intestinal putrefaction, carcinogen production, liver damage, production of 
toxins, diarrhea and/or constipation, and intestinal infections (Wallace et al., 2011). 
2.1.2 Development of gut microflora 
The human intestinal tract is home to over 14 log microorganisms; 10 times greater than 
the total number of somatic and germ cells found in the human body (Bäckhed et al., 2005).  
―Our gut microbiota can be pictured as a microbial organ placed within a host organ: It is 
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composed of different cell lineages with a capacity to communicate with one another as well as 
the host; it consumes, stores, and redistributes energy; it mediates physiologically important 
chemical transformations; and it can maintain and repair itself through self-replication.‖ 
(Bäckhed et al., 2005) 
At birth the gastrointestinal tract is a sterile environment (Wallace et al., 2011). This 
assemblage of bacteria begins colonizing immediately after birth. Factors such as vaginal versus 
caesarean birth, as well as breast versus formula feeding are among the first to impact gut 
flora(Guarner & Malagelada, 2003). The only significant changes in the gut microbiota occur 
during infancy, after which a relatively stable environment is maintained throughout childhood 
and adult life (Favier, Vaughan, De Vos, & Akkermans, 2002; Zoetendal, Akkermans, & De 
Vos, 1998). The initial colonization heavily influences the final composition of the permanent 
flora in adults (Guarner & Malagelada, 2003).  
Healthy individuals typically have an intestinal habitat of 300 to 500 different species of 
bacteria (Guarner & Malagelada, 2003).  Bacteria colonize all of the physically available space 
along the gastrointestinal tract, with varying distribution. Each species occupies a niche in a 
particular habitat. The gastrointestinal tract is deceptively long.  It has been calculated to be 150-
200 m2  (Waldeck, 1990). Surface area of the gastrointestinal tract, specifically the small intestine 
is increased via folding, ‗e.g.: three-fold by forming circular folds, 7-10 fold by folding of the 
epithelium (intestinal villi) and 15-40 fold by the formation of microvilli in the enterocyte 
resorptive luminal membrane.‘ (Holzapfel, Haberer, Snel, & Schillinger, 1998).  The gut 
microflora increases in quantity and diversity as one moves along the gastrointestinal tract. In the 
stomach, the bacterial count is about 101cells/gram, and includes Lactobacillus, Veillonella, and 
Helicobacter.  The duodenum, jejunum and ileum of the small intestine possess bacterial counts 
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of 103, 104, 107cells/gram respectively which include Bacilli, Streptococcaceae, Actinobacteria, 
Actinomycinaeae, and Corynebacteriaceae. Lastly, the colon houses a bacterial count of 
1012cells/gram consisting of Lachnospiraceae and Bacteroidetes.  
 
 
 
Figure 2 Gut microbiota. a) The numerical breakdown of gut microorganisms along the GI tract. 
b) The bacterial composition of the intestinal wall. c) The evolution of bacteria during aging. 
 
Current sample collection methods used to analyze diversity of the microbiota are limited 
by the difficulty of access. Fecal samples are commonly used due to the convenience of 
collection. However, bacteria from these samples do not fully represent the total population of 
the gut microbiota. Investigators have begun utilizing methods such as molecular finger printing 
and 16S ribosomal DNA (rDNA) to explore this ecosystem. Various studies have shed light upon 
the composition as it has been accessed. The gut microbiota is predominately strict anaerobes, 
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but facultative anaerobes and aerobes are also present. To date, over 50 bacterial phyla have been 
identified in the human gut, but two remain in the forefront of importance Bacteroides and 
Firmicutes; occurring in lower magnitude are Proteobacteria, Verrucomicobia, Actinobacteria, 
Fusobacteria, and Cyanobacteria (Eckburg et al., 2005; Schloss & Handelsman, 2004).  
Each phyla, species, and strain of bacteria has an individual role that often time only they 
specifically are able to perform. Certain bacteria are able to metabolize a wide variety of 
substrates, while others have more specialized abilities.  
About 30% of the gut microflora is composed of Bacteroides of the phylum 
Bacteroidetes (Salyers, 1984). Notable species to mention include B. thetaiotaomicron, 
B.vulgatus, B. distasonis and B. fragilis (Salyers, 1984). The Bacteroides species are recognized 
as starch degraders. Additional strains have been found to degrade certain types of structural 
polysaccharides as well. The high population of Bacteroides in the gut is believed to be caused 
by the import of oligosaccharides for continued hydrolysis. 
 2.1.3 Changes in the composition of gut microflora 
The adult gut microbiota is primarily composed of non-sporing anaerobes, the most 
prominent being Bacteroides spp., Eubacterium spp., Clostridium spp., Lactobacillus spp., 
Fusobacterium spp., as well as a variety of other gram-positive cocci (Wallace et al., 2011). 
Present in fewer numbers are Enterobacteriaceae, methanogens and dissimilatorysulphate-
reducing bacteria (Wallace et al., 2011). The anaerobic environment, characteristic of the 
gastrointestinal tract, is produced by the metabolism of oxygen by the microbiota (Wallace et al., 
2011). The composition of the gut is individualized, and varies based on one‘s history and 
encounters with conditions such as acute diarrheal illness, diet, and antibiotic treatment (Guarner 
& Malagelada, 2003).  
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The organization of the symbionts remain relatively stable during adult life, however age-
related changes, such as changes in diet, environment and host immune system reactivity, 
influence the microbiota population composition (Hooper & Gordon, 2001; E. Woodmansey, 
2007). The changes that occur in microfloral bacterial populations can be seen in Figure 3. 
―Recent studies indicate shifts in the composition of the intestinal microbiota, potentially leading 
to detrimental effects for the elderly host. Increased numbers of facultative anaerobes, in 
conjunction with a decrease in beneficial organisms such as the anaerobic lactobacilli and 
Bifidobacteria, amongst other anaerobes, have been reported.‖ (E. Woodmansey, 2007). 
Additional studies have also concluded that with increasing age the number of viable 
Bacteroides decreases (Hopkins & Macfarlane, 2002; E. J. Woodmansey, McMurdo, 
Macfarlane, & Macfarlane, 2004). This is notable due to the nutritional versatility of the 
Bacteroides species. Bacteroides are capable of using a broad assortment of carbon sources and 
are believed to conduct the majority of the polysaccharide digestion in the colon (Salyers, 1984). 
The normal microbial balance of the elderly gut is very delicate therefore malfunctions in 
gastric function, or intestinal motility have a major impact on health. ―Changes at species level 
of such a nutritionally important sub-population could have considerable consequences for the 
elderly host, because of alteration in metabolic activities, and for other bacteria in the ecosystem 
that rely on a complex cross-feeding network within the gut.‖ (Gibson, Cummings, & 
Macfarlane, 1988) Reports of the changing microbiota of the elderly include increased numbers 
of lactobacilli, clostridia, and facultative anaerobes (T Mitsuoka, Hayakawa, & Kimura, 1974; 
Tomotari Mitsuoka, 1990). Decreases in bacteria such as F. prausnitzii, E. allii and other 
bacteria belonging to the E. rectal/ Roseburia group have been correlated with functional 
declines in the elderly microbiota production of butyrate (Biagi et al., 2010). These butyrate 
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producing bacteria also have anti-inflammatory properties, and population declines of these 
bacteria might support the inflamm-aging process in the gastrointestinal tract of elderly people. 
Loss in butyrate production may also play a role in the development of degenerative diseases and 
anorexia (Donini, Savina, & Cannella, 2010; Guigoz, Doré, & Schiffrin, 2008).   
 Essentially, the stability of the gut microbiota of the elderly is affected by the 
physiological changes of the gastrointestinal tract stimulated by increasing age; coupled with 
factors such as changes of lifestyle and diet, and diminished performance of the immune system 
(Biagi et al., 2010). 
 
Figure 3 Changes of intestinal microflora with age.   (Tomotari Mitsuoka, 1978) 
 
2.1.4 Physiological changes of the gut with age 
Natural declines in physiological function commonly occur with age. This decline may 
indirectly alter the composition of the gut microflora due to the influence of absorption and/or 
metabolism of nutrients. Decreased muscle bulk coupled with tooth loss causes mastication, and 
in some cases, swallowing difficulties (Karlsson et al., 1991; Newton et al., 1993). Diminished 
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sensory sharpness leads to foods tasting bland (Weiffenbach et al., 1982). The combination of 
which can bring about the nutritionally imbalanced diet of the elderly population.  
A major physiological change, reported by the elderly, in the gastrointestinal tract is the 
reduction in fecal weight (E. J. Woodmansey et al., 2004). ―Low fecal weights have been 
correlated to slow intestinal transit times and reduced excretion of bacterial matter .‖ (Stephen, 
Wiggins, & Cummings, 1987) Furthermore, increased retention time is associated with an 
increase in bacterial protein fermentation and consequently, the levels of ammonia and phenols 
generated in putrefactive processes in the gut.‖ (Macfarlane, Cummings, Macfarlane, & Gibson, 
1989)As a consequence of the decreased intestinal motility constipation occurs (Kleessen, 
Sykura, Zunft, & Blaut, 1997). The inability to effectively excrete proper levels of harmful 
bacteria unfavorably alters the fermentative processes of the gut (Brocklehurst, 1972; Macfarlane 
et al., 1989).  Thus affecting the intestinal ecosystem homeostasis (Biagi et al., 2010). 
Barrier function is another component of the gut potentially compromised with increasing 
age. Evidence of barrier importance has been demonstrated via germ-free animals, whose 
susceptibility to infections was lessened by the protection of the intestinal barrier (Wallace et al., 
2011). The function of the barrier is carried out by a network of the physical components of the 
intestine; villi height, crypt depth, and thickness of mucus. The size and surface area of villi 
determine the amount of nutrients able to be absorbed (Yang et al., 2009).  Therefore, larger 
surface areas, allow larger amounts of nutrients to be absorbed. Similarly, increases in crypt 
depth are consistent with digestive efficacy (Guan, 2000). The role of crypts in the intestines is 
believed to be associated with facilitating digestion and absorption. Increased crypt depth means 
increased crypt cell number, thus increasing digestive efficacy (Guan, 2000). 
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2.1.5 Effect of gut microflora on the immune function 
The three components of the GI ecosystem, the microbiota, the intestinal epithelium, and 
the mucosal immune system, are all vital to the functional and developmental maturity of the 
system (Tiwari, Tiwari, Pandey, & Pandey, 2012). The convergence of the microbiota and 
immune system begins at infancy, and aids in the development of the immune system. This 
partnership lasts throughout an individual‘s lifetime. This network protects against potentially 
harmful antigens and microorganisms the human body may encounter from external exposure. 
The gut microbiota and gut mucosal surface coexist in close proximity to one another. The single 
cell epithelial layer must differentiate this high microbial presence from a persistent threat of 
microbial invasion. Humans have developed a specific gastrointestinal immune system in order 
to process this risk; to limit tissue invasion by intestinal microorganisms and to preserve the 
symbiotic nature of this interaction (Hooper & Macpherson, 2010). The intestinal microbiota is 
monitored by the lymphoid tissue, which maintains control by a ‗constitutive low-grade 
physiological inflammation‘.  This low grade inflammation is based on a network of positive and 
negative biological feedback processes. The organization of the gastrointestinal mucosal immune 
system facilitates the distinction between harmful pathogens and symbiotic microorganisms. 
Thus, generating a strong effector response towards the former and remaining tolerant to the 
latter. (Biagi, Candela, Fairweather-Tait, Franceschi, & Brigidi, 2012).   
Live bacteria manage the function of the immune system at systemic and mucosal levels. 
The management role of the microbiota entails guiding intestinal immune cells into their proper 
arrangement. Intestinal immune cells mediate tolerance-inducing responses and are active in host 
defense. The cells congregate at inductive sites such as Peyer‘s patches found in the small 
intestine, and lymphoid follicles, and colonic patches found in the large intestine; as well as 
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effector sites which include the epithelium of the intestine (Garrett, Gordon, & Glimcher, 2010).    
The gut epithelial is constantly communicating with the immune cells via intracellular signaling 
pathways (Collier-Hyams & Neish, 2005; Rumbo et al., 2004). Innate immune responses are 
activated by intestinal epithelial cells, which release chemokines and cytokines. These signaling 
proteins control dendritic cell and macrophage responses (Collier-Hyams & Neish, 2005). The 
coordination communication and placement of all the components within the network of the 
immune system contribute to the proper development of immune cell responses. These responses 
will be able to appropriately remove infectious agents and damaged tissues from the body, and 
maintain the state of homeostasis within the gastrointestinal tract. 
 
 
Figure 4 A detailed view of the intestinal and colon walls. 
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The barrier formed by the intestinal epithelium and the gut microbiota is designed to 
prevent the invasion or uptake of potentially pathogenic microorganisms, antigens, or other 
harmful compounds that enter the gut lumen (Holzapfel et al., 1998). Not only are the bacteria of 
the microflora efficient as a physical barrier, but are also efficient at digesting antigens. 
Specialized transport mechanisms in the villus epithelium and Peyer‘s patches are used to trigger 
specific immune responses to target antigens. This barrier remains stable in healthy individuals, 
and the human host is provided with protection as well as normal intestinal and immune 
function. 
Attachment of Lactobacillus and Bifidobacterium, specifically, onto the natural mucosal 
barrier prevents the attachment of potentially pathogenic microorganisms (Garcia-Lafuente, 
Antolin, Guarner, Crespo, & Malagelada, 2001). The gut microflora not only provides protection 
physically, using competitive exclusion by occupying attachment sites, but also by consuming 
the nutrients that pathogens would potentially use. This assemblage of microorganisms also 
produces antimicrobial compounds (Sekirov et al., 2010). 
2.1.5.1 Functional reduction of the immune system with advancing age 
 Due to the term elderly being used in reference to a population with varying health status‘ 
it becomes difficult to accurately define an age at which the gastrointestinal environment begins 
to experience age-related decline (Biagi et al., 2012). 
Immunosenscence is the process in which the functionality of the gastrointestinal 
immune system declines (Ostan et al., 2008; Shanley, Aw, Manley, & Palmer, 2009). 
Inflammageing is another health decline experienced by elderly individuals characterized by a 
chronic low-grad inflammatory status (Franceschi, 2007; Franceschi et al., 2007; Larbi et al., 
2008). The inflammageing process occurs at a localized area of the intestinal mucosa. 
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Continuous inflammation is believed to contribute to the systemic inflammation, which may 
affect or be affected by the gut microbiota. It is believed that the inflammatory process could be 
caused and/or cultivated by an immune response activated unusually by the gut microbiota; this 
could be due to decreased mucosal tolerance or age related microbiota composition changes, or 
possibly both (Guigoz et al., 2008). Moreover, deficiencies in nutrition,  age-related tissue 
weakness, and injuries may also contribute to the onset of a pathogenic inflammatory response to 
the presence of normally harmless symbiotic bacteria (Schiffrin, Morley, Donnet-Hughes, & 
Guigoz, 2010). 
2.1.6 Common factors of aging that can possibly affect gut microflora 
A variety of factors, or in some cases a combination of factors, onset by old age are 
believed to contribute to alterations in gut microflora composition as well as increased incident 
of illness/disease experienced by the elderly. Deterioration in dentition, salivary function, and 
digestion; changes in living arrangement, and/or socioeconomic status; decreased mobility and 
prevalence of disease may all affect the intestinal microbiota upon aging.  
Deterioration in dentition is often caused by the lost or reduction in the strength of the 
muscles necessary for mastication as well as tooth lose (Karlsson et al., 1991; Newton et al., 
1993). When older people experience weakness in chewing and swallowing their food it leads to 
a high likelihood of diet modification to conform to their mastication abilities. However, for 
muscle function the diet must include adequate amounts of protein, vitamins and minerals.  
Studies observing frailty in the elderly found a relationship between diet and physical 
strength, and correlated dietary magnesium with muscle capacity (Fiatarone et al., 1990).  Food 
sources highest in dietary magnesium include dark leafy greens, nuts and seeds, fish (mackerel), 
soy beans, whole grains, bananas and dried fruits. It was also found that subjects with the 
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weakest muscle strength had the lowest levels of circulating vitamin D. Food sources highest in 
dietary vitamin D include fatty fish such as salmon, tuna, and mackerel; beef liver, eggs, and 
fortified fruit juices. For elderly persons with preexisting mastication issues many of these food 
products become difficult to break down. Therefore some of the very food products that would 
provide the key nutrients needed for maintaining muscle strength are not consumable. As a result 
of this problem occurring with a variety of hard to eat foods, the diet becomes nutritionally 
imbalanced. This is important because the microorganisms of the gut use the nutrients consumed 
for fuel for the host as well as themselves. A nutritionally imbalanced diet leads to both host and 
microflora lacking vital nutrients. Ervin, 2008 found elderly individuals who had suffered tooth 
lose and rated their health as fair or poor generally consumed fewer servings of fruits and 
vegetables, ate a less varied diet and had a poorer quality diet than people with teeth(Ervin, 
2008). 
Changes in living arrangements and/or socioeconomic status after which elderly persons 
move to assisted living facilities are another major contributing factor. In 2009 Dean et al. 
reported that factors including appetite, knowledge of food, perceived distance to grocery stores, 
access to kitchen amenities or quality food items, and support from family and friends all 
contribute to the variety in the diet and nutritional balance of many elderly persons. Depending 
on the family circumstances some older individuals live alone, in day hospitals, or in long term 
assisted living facilities. Claesson et al. completed a study investigating the microbiota of elderly 
individuals of diverse living environments. Individuals residing in long term assisted- living 
facilities were found to have less diverse microbiota than those living independently. Results 
from this study also indicated that healthy diverse diets promote a more diverse gut microbiota.  
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Lastly and most commonly, elderly persons typically experience amplified frequency of 
disease. The difficulty of disease in this population is exacerbated by co-morbidity.  
2.1.6.1 Diet of the elderly 
The influence of diet on the gut microflora is seen as early as birth. As previously 
mentioned, the microflora of newborns differs depending on the consumption of breast milk or 
formula. Breast fed babies develop a simple microflora composed primarily of bifidobacteria. 
Formula fed babies have large numbers of bifidobacteria in addition to species such as 
bacteroides and clostridia (Hopkins, Sharp, & Macfarlane, 2002). The impact of one‘s diet 
continues into adulthood. The proportion of the macronutrients carbohydrates, protein and fat, in 
the diet directly influences the composition of the microbiota.  
Diet is the most controllable of all factors encountered by the elderly. Animal and small 
scale human studies have shown diet to influence microbiota composition over long periods of 
time (Hildebrandt et al., 2009; Mai, McCrary, Sinha, & Glei, 2009; Muegge et al., 2011). 
Incorporating a healthy diet is often the first strategy to preserve health among the elderly (Biagi 
et al., 2012). The diet provides nutrition and alters the environment for microbes in the 
gastrointestinal tract (Lee, 2013). A healthy diet can also impact gut transit time and 
pH.―Scientific and clinical evidence available to date indicates that diet is a major driving factor 
for the establishment of the gut microbiome. Slow digestible carbohydrates (human milk glycan, 
inulin and fructooligosaccharide), insoluble complex carbohydrates and protein diets favor the 
growth of Bacteroides, Clostridium, and Bifidobacterium. Fat on the other hand suppresses the 
number of Bacteroides, Clostridium, and Bifidobacterium; whereas polyphenols in general 
suppress Bacteroides, Clostridium, but enhance Bifidobacterium.‖ (Lee, 2013) 
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 Living arrangements must be taken into account when discussing the diet of the elderly. 
For those living in nursing homes or other assisted living facilities the composition of diet vary 
from elderly persons living independently at home or in the home of a relative. The healthiest of 
the elderly population have been found to be those living in a community setting, eating a 
balanced and variety diet leads to a distinct microbiota from those in long-term residential care 
(Claesson et al., 2012). 
2.1.6.2 Medical Drug Use of the elderly 
In 2004 Gurwitz completed a comprehensive national survey of the non-institutionalized 
adults in the United States and found that more than 90 percent of individuals 65 or older were 
using at least one medication per week. More than 40 percent use 5 or more different 
medications per week, and 12 percent use 10 or more different medications per week (NHTSA), 
2008). Of all the administered prescription drugs, the elderly receive 30 percent of these 
medications (Genser, 2008).  
2.1.6.2.1 Health benefits of medical drugs 
The positive attributes of medical drugs are evident by the extended lives elderly persons 
with diseases are able to live. These compounds successfully treat or alleviate ailments that at 
one time were considered fatal. Medication therapies are often used as primary and/or secondary 
defenses in disease prevention. Primary prevention occurs before the individual acquires a 
disease. The objective of primary prevention is to keep individuals from contracting the disease. 
This is accomplished via lifestyle modification and/or reducing exposure to disease causing 
agents. These primary prevention procedures typically reduce incidence and prevalence of 
disease. Secondary prevention occurs after disease has arisen, and serves to control disease 
progression. In these instances the disease is found early and is often treatable if not curable. 
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Aspirin, or acetylsalicylic acid, has a proven benefit for the secondary prevention of 
cardiovascular disease. An estimated 50 million people take aspirin daily as a means of treating 
or preventing cardiovascular disease (Chan & Graham, 2004). 
3 2.2 Medical drugs commonly taken by the elderly 
Common ailments suffered by the elderly are often treated with a range of medications, 
from non-steroidal anti-inflammatory drugs (NSAID), to acetaminophen (Tylenol). Medications 
are easily accessed over the counter, increasing the likelihood of purchase and self medicating. 
Non-steroidal anti-inflammatory drugs or NSAIDs are one of the most widely prescribed 
medications in the world, and provide analgesic, antipyretic and anti-inflammatory effects. This 
group of medications can be acquired by prescription or over the counter. The types of NSAIDs 
available over the counter (OTC) include aspirin such as Bayer ©, Bufferin ©, or Excedrin©; 
ibuprofen such as Advil© or Motrin IB©; or naproxen such as Aleve. These are also the 
prominent members NSAIDs. 
Many are commonly used to treat musculoskeletal and arthritic diseases, at higher 
prescription doses, by reducing joint inflammation. At a lower dose NSAIDs also treat a wide 
array of pain related issues such as headaches, muscle aches, trauma, dental extraction, and 
surgery. Of the three types of non-steroidal anti-inflammatory drugs, all block prostaglandins. 
Prostagladins are hormone like substances that triggers pain, inflammation, muscle cramps and 
fever.  
The active ingredient, acetylsalicylic acid, used in the first non-steroidal anti-
inflammatory drug, was synthesized by Felix Hoffman in 1897. Aspirin is not only commonly 
prescribed to elderly patients in its pure form, but it is also found as an ingredient in many other 
drugs.  
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2.2.1 Adverse effects of medical drugs on the gut microflora of the elderly 
The homeostasis of the intestinal microflora must be maintained in order for good health 
to prevail. Advancing age is commonly associated with rising prevalence of disease, the 
corresponding medication use for treatment can alter the composition of the gut microflora 
(Tiihonen et al., 2010). ―Elderly patients are the recipients of more than 30% of all prescription 
drugs, often given as multiple treatments, so are at higher risk of compromised nutritional status 
because of drug-nutrient interactions, for example, loss of body electrolytes.‖ (Genser, 2008) The 
elderly are twice as likely to experience an adverse reaction to medical drugs as their younger 
counter parts.  
There are many reported adverse effects associated with the drugs commonly prescribed 
to elderly patients. NSAID drugs are linked to gastric and duodenal damage (Bjarnason & 
Takeuchi, 2009; Laine, 1996; Soll, Weinstein, Kurata, & McCarthy, 1991) and opioids to 
constipation (Pappagallo, 2001). The more common locations effected by adverse reaction of 
drugs are the small and large intestine, which  represent  20 to 40 percent of drug side effects 
(Zeino, Sisson, & Bjarnason, 2010). ―The high incidence of small and large intestinal side effects 
of drugs is due to the fact that both organs are controlled by a highly delicate interaction between 
the autonomic sympathetic and parasympathetic nervous system, the high metabolic activity of 
cells involved in absorption and secretion and the intestine is exposed to the greatest 
concentration of microbes and is exposed to high drug concentration. The potential for a drug to 
adverse affect these pathways is therefore substantial.‖ (Zeino et al., 2010) 
Extensive use of NSAID medications is known to affect intestinal health. Damage to the 
mucosa of the gastrointestinal tract is the most common adverse effect of non-steroidal anti-
inflammatory drugs (Bjarnason, Hayllar, MacPherson, & Russell, 1993). Other side effects 
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include gastric pain, heartburn, nauseas, vomiting, bleeding, perforation, ulceration, dyspepsia, 
and in severe instances hemorrhage and death (Rampton, 1987). It has been shown that 60% of 
patients regularly taking NSAIDs have developed intestinal inflammation associated with protein 
and blood loss; even upon discontinuing use of the medication patients continued to experience 
intestinal inflammation for up to 16 months (Bjarnason et al., 1987). 
One study found that NSAID users have a three time greater risk to develop serious 
adverse gastrointestinal effects than those that do not use NSAID medication. Researchers also 
found that additional risk factors for these potential hazards include being age 60 years or above, 
having a previous history of gastrointestinal problems, or are simultaneously using 
corticosteroids (Gabriel, Jaakkimainen, & Bombardier, 1991). More than 7000 hospitalizations 
and 7000 deaths annually in the United States can be attributed to NSAID induced 
gastrointestinal pathology (Davies & Wallace, 1997).   
A very common NSAID drug is aspirin. Endoscopic evidence for the damage aspirin can 
cause the gastrointestinal tract was found as early as the 1930s by Douthwaite and Lintott. Later 
in the 1970s investigators proved that aspirin inhibited prostaglandin production, which is 
involved in inflammation. The standard dosage of aspirin is estimated at 325 mg/day. This 
dosage has been linked to higher risks of gastrointestinal bleeding, including fatal bleeding, in 
comparison to the lower dose of 75 mg (Campbell, Smyth, Montalescot, & Steinhubl, 2007). 
Even when administered at low doses aspirin has been found to cause peptic ulceration, ulcer 
bleeding, anemia, and the need for transfusion(Roderick, Wilkes, & Meade, 1993; Slattery, 
Warlow, Shorrock, & Langman, 1995). Individuals are continually directed to take high doses of 
aspirin, despite studies which have shown that higher doses confer no greater benefit in 
thrombotic event prevention than the lower doses (Reilly & FitzGerald, 1987).  
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2.3 Probiotics 
In the early 20th century Eli Metchnikoff made the first observation of the positive role 
microorganisms play in human health. Upon studying rural populations in Europe, such as 
Bulgaria and the Russian Stepps, Metchnikoff discovered these populations living long lives by 
means of diets consisting largely of milk fermented by lactic acid bacteria (Ogueke, 2010). 
Officially named ―probiotics‖ in 1953, these microorganisms were a group of bacterial strains 
found to positively enhance the function of the digestive tract (Tiwari, 2012). Later in 2002 the 
Food and Agriculture Organization (FAO) of the United Nations defined probiotics as ―Live 
microorganisms administered in adequate amounts that confer a beneficial health effect on the 
host.‖ 
The term probiotic is not synonymous with the naturally occurring beneficial bacteria of 
the gastrointestinal tract, although species may be isolated from this source (Douglas & Sanders, 
2008). There are guidelines published by the FAO defining probiotics at the strain level (Nations, 
2006). Identification of the probiotic strain must properly include the genus and species level in 
accordance with current scientific practice, and be named in accordance with current 
nomenclature. With the guidelines in place the term probiotic cannot be used as a ―catch all‖ to 
describe undefined combinations of microorganisms (Surawicz, 2004). Once defined, probiotic 
strains should be submitted into an international culture collection (Euzéby, 2008). This allows 
members of the scientific community the opportunity to replicate published studies.  
It is important to take note of the difference between a live, active culture and a probiotic. 
Live, active cultures are commonly found in fermented foods, especially fermented dairy 
products, but also vegetable products such as sauerkraut. Products containing live active cultures 
are not tested for their ability to confer health benefits, as is required of probiotics. Live active 
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culture containing products are only tested for their fermentation properties. Therefore, unless 
live cultures contribute documented health benefits, they should not be called probiotic (Sanders, 
2009). 
Probiotic bacteria have an array of biological effects, which include, enhanced: antibody 
production, natural killer cell activity, epithelial barrier function, tight junction protein 
phosphorylation, and epithelial cell glycosylation; modulation of: host immune response, 
dendritic cell phenotype and function, and apoptosis; altered cytokine release; induction of: 
regulatory T cells and PPAR-g; inhibition of: proteasome activity and pathogenic bacterial 
invasion; and blockade of bacterial adhesion to epithelial cells (Tiwari, 2012). The previously 
mentioned barrier created by the gastrointestinal tract and the gut-associated immune system are 
vital components of human health.  The gut microbiota is an active element in this mucosal 
barrier (Kalliomäki, Salminen, & Isolauri, 2008). 
2.3.1 Functionality (Viability) of Probiotics 
In order for bacteria to be considered for use as a probiotic there are specific functional 
characteristics it must possess. Probiotic bacteria should be first and foremost nonpathogenic and 
nontoxic. There must be a beneficial effect exerted on the host as a result of the bacteria. It is 
essential the bacteria be able to survive the harsh environment of the gut and metabolize there. 
By remaining alive in large numbers when reaching the intestines, bacteria should be able to 
maintain the balance of the microflora; promoting the growth of friendly bacteria and inhibiting  
harmful ones, which is ideal (Tiwari et al., 2012). A good sensory quality is another sought out 
virtue if the bacteria it is to be incorporated into a food. 
In order for the claimed health effects of the probiotic bacteria to be sustained, the 
microorganisms must remain viable during the processing and storage stages (Song et al., 2012). 
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This refers to an effective number of viable cells available once the product reaches consumers. 
Labeling is also important; probiotic labeling must provide truthful and adequate information to 
consumers (Sanders, Gibson, Gill, & Guarner, 2007). 
In preparing microorganisms for probiotic use, manufacturers must also take precautions.  
When infusing foods with probiotic bacteria, specifically lactic acid bacteria (LAB), the 
organisms are present as active microorganisms. This limits the shelf life of the food product to 
about a month. ―Strains should be adapted to a suitable carrier or fermentable substrate (e.g. 
milk), and the final product should have an acceptable shelf-life and sensory attributes such as 
color, taste, aroma, and texture.‖ (Holzapfel et al., 1998). The bacterial strains present in the 
product should remain viable in large numbers and maintain their metabolic activity even after 
the expiration date. Dietary supplements, contain the microorganisms in a dormant desiccated 
state, which increases shelf life to up to 24 months given that the water activity is kept low 
(<0.20) (Ouwehand, Salminen, & Isolauri, 2002). Water activity, in addition to temperature and 
pH are major factors in producing probiotic food products and other supplements.  
Identifying bacteria worthy of probiotic use is a rigorous process, scientists must test all 
bacteria that are to be considered, because probiotic effects are often strain specific, the benefits 
associated with one species or strain is not necessarily true for others (Williams, 2010). This 
applies even within the same species. It is also important to note that any bacterial strain to be 
used for human consumption be tested and approved especially if the strain comes from a non 
human source.  
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2.3.1.1 Safety of Probiotics 
2.3.1.1.1 Consumers 
Consumers should not take probiotic consumption lightly.  It is important to recognize 
the dynamics of bacterial strains present in the product as well as the specific health promotion 
the product confers. Variances in genera, species, and strains of bacteria from product to product, 
lead to differences in the intent of the product. Claims of efficacy labeled on probiotic 
supplements, or products in general, should be target specific, and only made upon successful 
testing  (Sanders, 2009). 
Although foods can never be guaranteed 100% safe, the level of harm to the general 
population of healthy individuals consuming probiotics must be low. For probiotic drugs, 
however, safety also includes a balance of side effects and potential benefits. Due to the 
distinction in standards of safety between probiotic foods and drugs, susceptibility of the target 
population determines the proper terminology.  The use of the term probiotic drug is advised by 
Sanders 2009, to be reserved for a probiotic being administered to an unhealthy population to 
cure, treat, or prevent disease. Although considered safe, probiotics could potentially cause side 
effects in vulnerable individuals such as systemic infections, harmful metabolic activities, 
excessive immune stimulation, and gene transfer(Philippe Marteau, 2001; Philippe Marteau & 
Seksik, 2004). 
The most commonly used bacteria in probiotics; Lactobacillus, Bifidobacterium, 
Saccharomyces, and S. thermophilus all have excellent safety records. These species of probiotic 
bacteria hold status as GRAS (generally recognized as safe). This safety covers all age groups as 
well as vulnerable individuals with compromised immune systems (Del Piano et al., 2006). 
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2.3.1.1.2 Manufacturing 
Manufactures must follow a strict process for probiotics prior to products reaching the 
market. Figure 5 demonstrates the flow of this process beginning with the identification of 
strains. Probiotic strains are identified by genus, species, and strain using phenotypic and 
genotypic methods. Once recognized, strains are input into the international culture collection. 
Strains are then evaluated for safety and characterized for function. Potential pathogenicity is 
tested beginning with the historical epidemiology of the strain. Assessment of probiotic strains 
also includes the potential to cause inadvertent disease by way of toxicity, accidental systemic 
exposure, and/or administration to vulnerable individuals (Sutton, 2008). The safety evaluation 
and characterization of function are conducted via in vitro and animal studies. Upon successful 
completion of these tests strains then move on to human studies. Human studies are conducted 
using randomized, placebo-controlled, double blind designs. Tests are repeated in order to 
confirm results, and ensure the effectiveness of probiotics compared to customary treatment. 
Probiotic foods are then manufactured. Labels for these products must include ingredients 
(genus, species, strain), minimum number of viable bacteria at the end of the product shelf life, 
storage conditions, and company contact information.  
According to the Dietary Supplement Health and Education Act (DSHEA) manufacturers 
are responsible for ensuring that dietary supplements manufactured or distributed are safe. 
Moreover any claims made regarding the supplements must be backed by substantial evidence to 
prove they are not false or misleading (Venugopalan, Shriner, & Wong-Beringer, 2010). 
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Figure 5 Preparations taken for labeling probiotic supplements. 
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2.3.2 Health benefits of probiotics 
In recent years there has been a dramatic rise in the interest of probiotics due to 
significant benefits imparted on human health. Scientific evidence supporting the health claims 
of probiotics stem from in vivo and in vitro studies. Legitimate research groups conduct these 
studies and publish the findings in peer-reviewed journals (Gorbach, 2002; Vasiljevic & Shah, 
2008). Specific health benefits are contributed by specific strains. Table 1 provides a list of 
probiotic stains and their associated health benefit.  
 
Table 1  
Health benefits and associated probiotic strains. 
Probiotic Strains and associated health benefits 
Health Benefit  Probiotic Strain(s) 
Immune system stimulation L. acidophilus, L. casei, L. planetarum, L. 
delbruekii 
Anti-tumor activity L. acidophilus, L. casei, L. planetarum, L. 
delbruekii, L. bulgaricus, L. helveticus 
Protection against acute diarrhea L. bulgaricus, L. acidophilus, L. bifidus, L. casei 
 
Lactose tolerance improvement L. bulgaricus, L. bifidus, L. acidophilus, L. 
sporogenes 
Lowered blood cholesterol levels L. acidophilus, L. sporogenes, L. bifidus 
Improved nutrient absorption and toxin elimination L. planetarum 
Protection against antibiotic associated diarrhea L. acidophilus, L. bulgaricus 
Improves Inflammatory Bowel Syndrome (IBS) L. sporogenes 
Protects against vaginal yeast infections L. fermenti, L. acidophilus, L. bifidus 
33 
 
 
Some of the most important functional effects, backed up by scientific evidence, have 
been summarized by Salminen et al. (1996), and include aspects such as immune modulation and 
strengthening the gut mucosal barrier, due to: (1) gut microflora modification, (2) adherence to 
the intestinal mucosa with capacity to prevent pathogen adherence or pathogen activation, (3) 
modification of dietary proteins by the intestinal microflora, (4) modification of bacterial enzyme 
capacity especially of those suggested to be related to tumor induction, and (5) influence on gut 
mucosal permeability.‖(Holzapfel et al., 1998) While many of these benefits are established and  
well documented, some show great potential in animal models, and need claims validated by 
human studies (Vasiljevic & Shah, 2008).  
One way in which probiotic bacteria are believed to improve human health is by altering 
the composition of the normal intestinal microflora. By displacing potentially harmful bacteria 
such as clostridia and coliforms, and replacing them with good bacteria such as lactobacilli 
and/or bifidobacteria host health is positively impacted (Ouwehand et al., 2002). In the same 
scenario, increasing the number of good bacteria is also beneficial to host health. Competition for 
attachment sites in the gastrointestinal tract is another benefit probiotic bacteria provide human 
hosts. Many strains of bacteria have been found to inhibit adhesion and displace pathogenic 
bacteria such as Salmonella, Escherichia coli, Listeria monocytogens, Staphylococcus aureus, 
and Clostridium difficile (Collado, Meriluoto, & Salminen, 2007). Investigation of other 
probiotic bacteria has led to findings supporting reduction of atopic eczema, vaginal infections, 
immune enhancement, rheumatoid arthritis, and liver cirrhosis (Gueimonde, Kalliomäki, Isolauri, 
& Salminen, 2006; E. Isolauri, Sütas, Kankaanpää, Arvilommi, & Salminen, 2001).  
A specific health issue in which probiotics have been found advantageous is lactose 
intolerance. As infants all humans are born with the enzyme lactase (β-galactosidase) which 
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hydrolyses lactose to glucose and galactose in order to be absorbed in the small intestine (Adams 
& Moss, 1999; Sanders, 2000). About two-thirds of the world‘s population suffers from lactose 
intolerance. These individuals do not possess this lactase (β-galactosidase) enzyme, and any 
ingested lactose cannot be digested which leads to the gut microflora attacking the lactose. This 
microbial attack occurs in the colon and produces abdominal discomfort, flatulence, and 
diarrhea. However, when lactose intolerant individuals consume fermented milk products the 
effects do not occur or are less severe. Researchers have found this to be due to the presence of 
lactase in the probiotic products with incorporated lactic acid bacteria. The lactase is lysed by 
bile when the bacteria reach the intestinal lumen, and acts on the lactose that has been ingested. 
Thus relieving lactose intolerance symptoms (Tuohy et al., 2003).  
Researchers observed significant decreases in small bowel lesions (associated with low 
dose aspirin use) in a study of Lactobacillus casei as a treatment option.  This inquiry and others 
like it have led researchers to believe that daily consumption of probiotics can potentially aid in 
gastrointestinal health against medications like aspirin. Amplified probiotic bacteria count in the 
gut microbiota better equip individuals when medical drugs are administered on a daily basis. 
The drugs will not diminish as many positive bacteria. Table 2 lists many commonly studied 
probiotics and their associated health benefits.  
2.3.2.1 Immunity  
Probiotic testing has revealed promising results in the ability of the bacteria to enhance 
immune responsiveness.  The probiotic bacteria enhance immune responsiveness by 
supplementing more beneficial bacteria to the preexisting microbiota of the host. The microbiota, 
which is an active member of the intestinal defense, is charged with the responsibility of 
maintaining immune responses, and sensitivity to potentially pathogenic bacteria. A LAB strain, 
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Bifidobacterium lactisHN019, was recently found to enhance nonspecific immune functions. 
―Namely leucocyte (lymphocytes and phagocytes) proliferation, enhance phagocyte production 
and proinflammatory cytokine production.‖ (Tuohy et al., 2003) Studies have also shown B. 
lactis HN019 to increase peripheral blood leucocytes and natural killer cells in healthy 
volunteers including the elderly; these attributes were observed to be active in the tumor and 
viral destruction (Gill, Cross, Rutherfurd, & Gopal, 2001). 
Dietary Lactobacillus rhamnosus HN001 has been investigated and proven in human 
studies to enhance the natural immunity in consumers (Gill et al., 2001). Researchers also 
suggested the use of the probiotic supplement in optimizing immune response in the elderly. L. 
rhamnosus GG was also proven in its ability to improve immune response by way of preventing 
atopic disease in high-risk children (Kalliomäki et al., 2008).  
Other therapeutic applications of probiotics were observed by Rosenfeldt et al. who 
demonstrated L. rhamnosus19070-2 and Lactobacillus reuteri DSM 122460 benefit in the 
treatment of atopic dermatitis in children (Tuohy et al., 2003).  
2.3.2.1.1 Probiotics augment gut barrier mechanisms 
The intestinal barrier has a variety of components working in conjunction to protect the 
body from infection as well as absorb key nutrients. As previously discussed the physical 
components of the barrier such as the crypt depth, villi height and thickness of mucus are vital in 
barrier function. The size as well as the surface area of villi determine the amount of nutrients 
that are able to be absorbed (Yang et al., 2009). Larger surface area, allows larger amounts of 
nutrients to be absorbed. Similarly, larger crypt depths are associated with improved digestive 
efficacy (Guan, 2000). The crypts in the intestines are believed to facilitate digestion and 
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absorption. Larger crypt depth means increased crypt cell number, thus increasing digestive 
efficacy (Guan, 2000). 
 The importance of the microbial component of the barrier is seen in the absence of gut 
microbiota, during which antigen transport is increased. Thus confirming the role of the gut 
microflora in the defense barrier function (Tiihonen et al., 2010).  Probiotic bacteria further 
enhance this barrier function by increasing production of intestinal mucus, effecting tight 
junction proteins, heightening the response of mucosal immunoglobulin A, introducing cellular 
heat-shock proteins, as well as increasing stimulation of defensin production (Wallace et al., 
2011). 
2.3.2.1.2 Functional Enzymes produced by Probiotics 
Probiotic bacteria like Bifidobacteria have been known to stimulate the production of 
enzymes such assecretory immunoglobulin A (sigA) in vitro; an enzyme influential in intestinal 
barrier function. This enzyme inhibits invasion by pathogenic microbes and is an important 
component of the intestinal immune system (Hanson, 1998). sIgA is produced by 
immunoglobulin A plasma cells and forms the protective layer over the intestinal membrane 
surface. Lactobacillus GG has also been found to increase numbers of sIgA and 
immunoglobulin-secreting cells in the intestinal mucosa (Kalliomäki et al., 2008). 
2.3.2.2 Cancer 
The fight against cancer is a continual battle that has seen major advancements in the past 
decade. New treatments and possible cures are constantly being searched for. Researchers have 
found that probiotics help prevent the return of cancers like bladder and colorectal cancers 
(Elliott, Summers, & Weinstock, 2005). 
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Despite the fact that cancer can manifest in any individual, at any time, prevalent cases 
do arise in the elderly population. Reports on colorectal cancer (CRC) specifically, indicate that 
three-quarters of all incidences are random and the chance of getting this disease increases with 
age (Tuohy et al., 2003). Although specific species have not been targeted as responsible, many 
microorganisms in the gastrointestinal tract are capable of producing carcinogens and tumor 
promoters from dietary content. This excludes Bifidobacteria and lactobacilli which do not 
produce toxic or carcinogenic metabolites. A few species of the gut microorganisms that have 
been identified as stimulating enzyme activity leading to the  conversion of dietary products into 
toxic or carcinogenic products such as β-glucuronidase, β-glycosidase, azoreductase, 
nitroreductase, IO ‗hydratase-dehydrogenase‘ and nitrate/nitrite reductase, are clostridia and 
bacteroides (Tuohy et al., 2003).   
The consumption of probiotic bacteria acts to reduce the count of the potentially 
pathogenic bacteria in the gut that produce toxins and carcinogens. In humans this reduced risk 
of developing CRC has been proven, and human epidemiological studies have also suggested 
that probiotics in the form of products such as yogurt, may reduce the risk of large adenomas in 
the colon as well(Burns & Rowland, 2000).  
Dietary factors are major contributors to the risk of cancers; diets high in fat and red, 
processed, meat are associated with colon cancer (Bingham, 1999). Dietary factors that are 
associated with reduced risk of cancer include high consumption of fruits, vegetables, whole 
grain cereals, calcium, and fish (Bingham, 1999; Rafter & Glinghammar, 1998). Changes in the 
metabolic activity and composition of the gut microbiota can potentially mediate the effect of 
diet on the carcinogenic process.  Bacteria of the microbiota could have roles in the initiation of 
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colon cancer through production of carcinogens, cocarcinogens, or procarcinogens (Guarner & 
Malagelada, 2003).  
2.3.2.3 Obesity 
In general, the long standing cause of obesity has been considered to be eating in excess, 
and in some cases genetic predisposition accompanied by a lack of ample physical activity. 
Mounting new evidence suggests the gut microbiota plays a role in the mechanism of the disease 
of obesity.  Research has associated gut microbiota with intestinal permeability, systemic 
quantity of adipose tissue and body weight. The original link between gut microflora and weight 
gain was a result of studies observing dietary fiber intake. In these studies decreasing dietary 
fiber intake resulted in excess body weight and diabetes; the hypothesized cause of this result 
was a change in gut microbiota due to an alteration in nutrient supply and digestion. However, 
consumption of a high fat diet has been found to decrease the total number of bacteria in the gut 
as well as promote the growth of gram-negative bacteria.  
―Four bacterial mechanisms have been identified to result in excess bodily energy gain: 
(1) microbiota increase energy bioavailability by transforming increased proportions of non-
digestible food into biochemically absorbable nutrients; (2) the influence of intrinsic bacterial 
metabolism to generate and raise systemic levels of SCFAs to activate triglyceride synthesis; (3) 
high fat diets can result in a responsive bacterial metabolism resulting in pathology (such as 
microbial conversion of choline to methylamines leading to a choline deficient state, which 
induces liver disease); and (4) the ability of the microbiome in regulating gut gene expression to 
favor an obese state. Obese humans also demonstrate an alteration of the Firmicutes to 
Bacteroidetes ratio that can be altered by weight loss.‖ (Ley et al., 2005; Ley, Turnbaugh, Klein, 
& Gordon, 2006) 
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2.3.3 Lactobacillus and Bifidobacterium 
Lactobacillus and Bifidobacterium are members of a group of bacteria known as lactic 
acid bacteria (LAB), and are from the phylum Firmicutes and Actinobacteria respectively. Lactic 
acid bacteria (LAB) encompass gram positive, non-spore-forming, catalase-negative bacterial 
species (Otieno, 2011). This group also includes Streptococcus, Enterococcus, Leuconostoc, and 
Pediococcus (Mombelli & Gismondo, 2000). Most probiotics share an optimum growth 
temperature  of 37°C and optimum pH  for initial growth is 6.5-7.0; although strains such as L. 
casei prefer temperatures of 30 °C (Von Wright & Axelsson, 2011).  Bifidobacteria are 
taxonomically distant from lactic acid bacteria, but are grouped together because of the shared 
metabolic end product, lactic acid; in addition they commonly share habitats, for example the 
intestinal tract and dairy products (Ouwehand et al., 2002). 
Lactobacilli are facultative anaerobes, gram positive, non-spore forming rods, they are 
usually non-motile, catalase negative, and do not reduce nitrate. The genus Lactobacillus belongs 
to the phylum Firmicutes, class Bacilli, order Lactobacillales, family Lactobacillaceae (Garrity, 
Bell, & Lilburn, 2004). The population of Lactobacillus in the gastrointestinal tract includes a 
variety of species and subspecies. Six species in particular are commonly isolated from humans: 
L. acidophilus, L. salivarius,  L. casei, L. plantarum, L. fermentum, and L. brevis (Mikelsaar, 
Mändar, & Sepp, 1998). Lactobacilli strains are versatile and capable to adapting well because of 
the diversity in the strains. Fermentation process, bacteriocin, and hydrogen peroxide production 
vary among the strains.  
Bifidobacteria are anaerobes (although there some species capable of tolerating oxygen), 
also gram positive, non-spore forming rods, but possess a characteristic ―Y‖ or club-shape 
morphology. Up to 25% of the microorganisms in the gut are bifidobacteria. Nine species that 
40 
 
 
have been isolated from humans are B. bifidum, B. longum, B. infantis, B. breve, B. adolescentis, 
B. angulatum, B. cantenulatum, B. dentium, and B pseudocatenulatum (Ballongue, Salminen, & 
Wright, 1993). 
―These bacteria produce lactic acid, acetic acid, and propionic acid, which lower the 
intestinal pH and suppress the growth of various pathogenic bacteria, thereby reestablishing the 
balance of the gut flora.‖ (Alvarez-Olmos & Oberhelman, 2001; Doron & Gorbach, 2006).  
2.3.3.1 Role of lactobacilli and Bifidobacteria in human health 
The health promoting benefits of lactobacilli and bifidobacteria have been evident since 
the early 1900s when the first reports were made. French scientist Tissier recommended treating 
infantile diarrhea with large doses of bifidobacteria, and Nobel laureate Ilya Metchnikoff 
suggested longevous effects from use of lactic acid bacteria of sour dairy products (Tissier, 
1907).  
Lactobacillus and Bifidobacterium are the two most common bacterial genera used in 
probiotic products. Both bacteria can be found naturally in the gut microflora. The genera are 
known to release short chain fatty acids which provide an energy source for the intestinal 
membrane, promote intestinal epithelium repair, as well as improve the local blood supply (Yang 
et al., 2009). Research thus far has provided evidence of the clinical effects certain probiotic 
strains confer, such as Lactobacillus rhamnosus GG, L plantarum 299v, L casei, and L. 
johnsoniiLa1; these strains aid in the treatment and/or prevention of intestinal origin (Hamilton-
Miller, 2004). 
The value of lactic acid bacteria to human health revolves primarily around prevention 
and treatment of gastrointestinal diseases. Examples of gastrointestinal diseases include irritable 
bowel syndrome (IBS), infectious diarrhea, and inflammatory bowel disease (IBD). Irritable 
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bowel syndrome comes with an assortment of functional problems in the gut including, 
constipation, intestinal pain, bloating, and diarrhea. An estimated 10% of the western population 
has experienced symptoms of IBS (Ouwehand et al., 2002).Although the cause of IBS remains 
unclear, species specific lactic acid bacteria have shown to improve symptoms (Ouwehand, 
Kirjavainen, Shortt, & Salminen, 1999).  
Infectious diarrhea is a gastrointestinal problem that has caused major concerns due to the 
mortality in children. The source of diarrhea cases are often speculated, some believe the disease 
to be caused by over population of pathogens in the gut with organisms like Clostridium difficile 
and Klebsiellaoxytoca, during antibiotic treatment, thus altering the balance of the microflora 
(Tuohy et al., 2003). Of the patients that receive antibiotics, 20% report cases of diarrhea (P 
Marteau, Seksik, & Jian, 2002). ―A recent meta-analyses has shown convincingly that 
prophylactic consumption of lactic acid bacteria reduce the risk of antibiotic associated diarrhea, 
Clostridium difficile associated diarrhea (Hempel et al., 2012), infectious diarrhea(Ritchie & 
Romanuk, 2012), and necrotizing enterocolitis (AlFaleh, Anabrees, Bassler, & Al-Kharfi, 
2011).‖ 
 Although the use of lactic acid bacteria as a treatment of chronic diarrhea remain 
inconclusive, indications of benefit in children have been found (Bernaola Aponte, Bada 
Mancilla, Carreazo Pariasca, & Rojas Galarza, 2010). In cases of infantile diarrhea, often caused 
by rotavirus, Lactobacillus rhamnosus GG has maintained a good track record of reducing the 
duration of the diarrhea by about 50% (E. e. a. Isolauri, 1999). Although a mechanism has yet to 
be clearly explained, possibilities of how probiotic bacteria stains alleviate diarrhea include 
increasing mucosal integrity, and stimulating the immune response.  In stimulating the immune 
response, it would be key to target antirotavirus-specific immunoglobulin (Ig) A. Combinations 
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of bacteria have also been used as in the case of Bifidobacterium bifidum and Streptococcuss 
thermophilus, and have shown their ability to reduce incidence of diarrhea caused by rotavirus 
(Saavedra, Bauman, Perman, Yolken, & Oung, 1994). 
The gastrointestinal disease inflammatory bowel disease (IBD) is a group of disorders 
with unknown cause. During IBD gut microflora is imbalanced and there are communication 
issues which result in the immune system not recognizing the gut microbiota. Characteristically 
patients suffer from chronic or reoccurring mucosal inflammation. There are two forms of IBD, 
Crohn‘s disease and ulcerative colitis (UC).  Lactic acid bacteria are being studied for their 
ability to reduce the rate of relapse in UC (Sang et al., 2010). The mechanism by which probiotic 
bacteria are believed to relieve symptoms and prevent recurrence is through regulation of the 
inflammatory response or alteration of the composition of the gut microbiota (Tuohy et al., 
2003). One case of relief gained from probiotic bacteria is the nonpathogenic strain E. coli Nissle 
1917, proven more effective in preventing relapse in Crohn‘s disease in patients versus a placebo 
(Rembacken, Snelling, Hawkey, Chalmers, & Axon, 1999). S. boulardii has also shown some 
success in relieving the symptoms of active Crohn‘s disease by reducing stool frequency and 
disease activity, as well as reducing the risk of relapse(Guslandi, Mezzi, Sorghi, & Testoni, 
2000). 
The benefits of the consumption of probiotic bacteria are not limited to gastrointestinal 
problems. Researchers have found that consumption of lactic acid bacteria reduces the infection 
rate and duration of symptoms in the common cold (Hao et al 2011). Colds are usually cause by 
viruses that escaped the immune system.  
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2.3.4 Application of probiotics 
The term probiotic is an umbrella term that encompasses foods, drugs, designer 
probiotics, and direct-fed microbials (Sanders, 2009).  Probiotic foods categorize food 
ingredients, dietary supplements, and food itself. Probiotic drugs categorize supplements used for 
their potential to prevent, treat, or cure disease. Designer probiotics categorize genetically 
modified probiotics. Direct-fed microbials categorize probiotics intended for animal use. 
Probiotic products can contain a single strain of a microorganism or a combination of several 
species (Williams, 2010). Among the strains most commonly used, and incorporated into 
products as probiotics include L. acidophilus and L. casei, due to their known health benefits. 
Although lactic acid bacteria like Lactobacillus spp. and Bifidobacterium spp. are the 
prevalent species used in dairy related probiotic products, other, non-lactic bacteria are also used. 
These non-lactic strains are typically used in lyophilized or encapsulated ‗pharmaceutical‘ forms 
(Holzapfel et al., 1998). Members of the non-lactic acid bacterial group include Bacillus and the 
yeast Saccharomyces (Mombelli & Gismondo, 2000). 
Of the commercially available probiotic products, many are not associated with scientific 
studies to prove the legitimacy of the health claim offered. It is important to research the 
products before consuming them. A few examples of products available that are tied to human 
studies documenting efficacy include: (capsules) Culturelle, Fem-Dophilus, and Align; 
(drinkable yogurt) Danimals; (yogurt) Activia and Yo-Plus; (powder) VSL #3 and Florastor; 
(fermented milk) DanActive, and BioK+CL1285 (Douglas & Sanders, 2008).    
2.3.4.1 Applications for the Elderly 
Mounting evidence supporting the importance of gut microbiota homeostasis to human 
health has led to the development of medical/ nutritional applications of probiotics targeted 
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toward the elderly population (Biagi et al., 2012). Incorporating probiotics into the daily diet of 
the elderly, or any individual seeking a healthier gastrointestinal system is a key aspect to 
longevity. This integration of probiotics into the diet can take place by way of food products as 
well as dietary supplements. 
2.3.4.2 Dairy Products 
One of the most common and historically documented medium for probiotic bacteria are 
dairy products. Due to the natural properties of dairy products and the refrigerated temperatures 
at which they are stored these products make suitable vehicles for probiotic bacteria(Song et al., 
2012). Dairy products containing probiotics commonly found on the market today include 
yogurt, cheese, and sour and fresh milk. The probiotic microorganisms are adequately delivered 
to humans because of the role dairy products play; providing an apt environment conducive of 
growth and viability (Gardiner et al., 1999; Phillips, Kailasapathy, & Tran, 2006; Ross, 
Fitzgerald, Collins, & Stanton, 2002; Saarela, Virkajärvi, Alakomi, Sigvart-Mattila, & Mättö, 
2006). 
2.3.4.3 Fruits and vegetables 
Emerging new interest has arisen in the use of non-dairy products as vectors of probiotic 
bacteria. The shift away from the traditional use of dairy goods derives from issues such as 
lactose intolerance and high levels of cholesterol in currently available dairy food. Among the 
requests from consumers as to new forms of probiotic products are vegetarian friendly products 
(Heenan, Adams, Hosken, & Fleet, 2004). As a result a wider array of probiotic products are 
being developed like fruits (Lavermicocca, 2006), vegetables (Yoon, Woodams, & Hang, 2006), 
legumes (Heenan et al., 2004) and cereal products (Helland, Wicklund, & Narvhus, 2004). 
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Delivering the probiotic bacteria to humans via fermented vegetables is possible, and this 
substrate has been tested in a variety of forms as a potential vehicle for probiotics.  
Table 2  
Nontraditional vectors of probiotics. 
Product      Bacterial strains 
1. Vegetable derived 
1.1 Tomato juice   L. acidophilus 
L. plantarum 
L. casei 
L. delbrueckii 
   1.2   Carrot juice   Bifidobacterium strains 
2.  Fruit derived 
   2.1 Banana puree   L. acidophilus 
2.2 Pomegranate   L. plantarum 
L. delbruekii 
L. paracasei 
L. acidophilus 
2.3 Orange juice   L. plantarum 
2.4 Noni juice    B. longum 
L. plantarum 
2.5 Cashew apple juice  L. casei 
3. Fruit and Vegetable mediums supporting various probiotic supplements 
3.1 Apple juice   L. acidophilus 
3.2 Beet juice    L. acidophilus 
     L. plantarum 
3.3 Cabbage juice   L. plantarum 
     L. delbruekii 
3. 4 Cranberry juice   L. rhamnosus 
3.5 Fermented banana   L. acidophilus 
3.6 Fermented banana pulp  L. acidophilus 
3.7 Ginger juice   L. rhamnosus 
     L. paracasei 
     L. plantarum 
3.8 Grape juice   L. reuteri 
3.9 Green coconut water  L. plantarum 
3.10 Passion fruit juice  L. acidophilus 
3.11 Peanut milk   Bifidobacterium strains 
3.12 Pineapple juice   L. casei 
3.13 Probiotic banana puree  L. acidophlius 
  
*Products available in the local market, in Greensboro, NC. 
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4 2.4 Probiotic Supplements 
There are a large number of probiotic products on the market today, and this number is 
steadily increasing. Consumer interest in function food, including those containing probiotics, 
has risen in the last 20 years (Song et al., 2012). Despite the predominant presence of probiotic 
food products available to consumers, probiotic supplements are becoming more popular. The 
Nutrition Business Journal 2011 reported that consumers spent 626 million dollars on probiotic 
supplements in 2010 (Coulston & Boushey, 2013).  
Probiotic dietary supplements are commercially available in the form of capsules, 
gummies, liquids, powders, and tablets. Capsules are produced by manufacturers when a drug 
cannot be compacted into a tablet; this form of the product also aids in swallowing problems. 
Capsules are produced in soft and hard forms; 1) hard capsules are more commonly seen, they 
are comprised of two halves fitted together and usually filled with a powder, 2) soft capsules are 
comprised of a single piece, and are appropriate for oils etc.  The technology for creating 
products like these probiotic containing capsules has been developed to protect the bacteria from 
damage during transit through the gastrointestinal tract. 
Probiotics are also available in the convenience of liquids, ranging from on-the-go single 
serving sizes to larger bottles for traditional dispensing. One benefit of the liquid probiotics is the 
coating effect it can have on the gastrointestinal epithelium. The bacteria are applied directly to 
the wall lining. This form of probiotic supplement does require refrigeration due to the presence 
of active, live microorganisms. Those liquid supplements containing freeze-dried bacteria do not 
require this refrigeration step. 
Powders are another method of administering probiotics. These products cater more 
towards individuals with difficulties swallowing capsules and tablets. The powder supplements 
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can be incorporated into foods and/or beverages. Consumers must be mindful of the temperature 
of the food or drink item they add the probiotic powder to, the supplement should not be added 
to hot foods or drinks. It is important that these products be kept dry, and stored in a dark 
location; moisture and oxygen can be destructive to probiotics.  
A broader selection of probiotic supplements to choose from, in regards to forms, 
benefits consumers and might increase the likelihood of purchase. The varieties of supplements 
available provide improved convenience of quick and easy administration to confer the same 
immune enhancing effects.  Throughout history probiotics have been predominantly included in 
dairy products; however with the increase in supplementation, consumers now have the ability to 
choose between the two products to reap the health promoting benefits of probiotic bacteria. 
 The elderly population benefits from the convenience of multiple probiotic supplements 
as well because the assortment of forms allows them to select a product that caters to their 
mastication or swallowing abilities. Elderly with weak swallowing abilities are now able to 
choose a liquid or powder form of a probiotic supplement for increased ease in administration.  
The increase in probiotic supplementation means a rise in the number of products 
available on the market. Probiotics, as previously mentioned encompasses many smaller 
subgroups of products including probiotic food, probiotic drugs, specialty probiotics and 
probiotic feed (for animals). The intended use of a probiotic agent determines its classification. 
Probiotic drugs and dietary supplements have differing regulatory requirements to abide by. A 
drug, defined by the Food and Drug Administration (FDA) is an article intended for use in the 
diagnosis, cure, mitigation, treatment, or prevention of disease (Del Piano et al., 2006).  
Probiotics intended for use as a drug, must go through the regulatory process as a drug. 
Probiotics intended for use as a dietary supplement, however is considered a ―food‖ and is 
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regulated by the FDA‘s Center for Food Safety and Applied Nutrition (Philippe Marteau & 
Seksik, 2004).  This exclusivity in definition is necessary, and in particular in reference to this 
study, due to the diversity among individuals being classified as elderly.  This study is targeting 
elderly individuals; this classification encompasses both healthy and unhealthy individuals. 
Some consumers will have preexisting conditions that the probiotics might be able to reconcile in 
addition to maintaining the microbial balance. 
With the rise in probiotic supplements available commercially, it is vital for consumers to 
research these products before making any general assumptions regarding probiotic use. 
Currently there is no legal definition for the term probiotic, and products on the market labeled 
―probiotic‖ may not be equip with the distinguished characteristics of stability, content, or health 
effects (Sanders, 2009). Researchers are adamantly testing the potential impact of probiotic 
strains on a growing array of conditions and subjects. ―A given probiotic, tested in different 
clinical situations, might exert a beneficial effect, show no effect, or result in an adverse effect. 
However, a negative or adverse effect in certain situations does not negate probiotic status. Such 
results do, however, stress the need to be specific about the benefits that are documented for each 
probiotic and the situations in which use is considered to pose an undue risk.‖ (Sanders, 2009) 
Consumers must also remember that probiotic supplements are intended to complement 
the diet, and therefore should not be used as a replacement for probiotic microorganisms 
provided through food consumption. Supplements alone are not sufficient, it is recommended for 
individuals to balance their supplement and dairy probiotic intake.  
2.4.1Viability of Probiotic cells in commercially available supplements 
 Viability of probiotic bacteria in commercially available supplements is crucial given that 
these microorganisms must survive the shelf life of the product and the harsh environment of 
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sections of the gastrointestinal tract, including an acidic stomach and enzyme and bile salt filled 
small intestine (Vasiljevic & Shah, 2008). In order for probiotic supplements or products to exert 
the health promoting effects claimed on the label, bacterial cells must remain viable up to human 
consumption. Probiotic products, such as yogurt, often claim to contain bacterial counts of up to 
several million live cells. Some researchers suggest that the minimum number of 
microorganisms required to confer positive health effects are 8 log CFU/mL (Shah, 2000).This 
large number of functional bacteria present during consumption ensures a sufficient amount of 
the probiotic microorganisms reach the large intestine. The sensitivity of these microorganisms 
to environmental conditions such as water activity, temperature, acidity, and redox potential 
(presence of oxygen) can lead to the probiotic cells dying or being present in numbers lower than 
advertised, at time of consumption; factors such as processing, storage, and time passed before 
products are eaten(Siuta-Cruce, 2001; Vasiljevic & Shah, 2008). 
Despite the importance of characteristics such as population count and viability in respect 
to probiotics in commercially available products, very few studies have been conducted 
substantiating the presence and quantity of probiotic bacteria claimed in many of the products on 
the market. In 2006,  Ibrahim and Carr conducted a study investigating the viability of 
bifidobacteria in commercial yogurt products purchased in Greensboro, North Carolina and 
found that only 44  out of the 58 commercial yogurt products (76%) tested contained viable 
cultures (S. Ibrahim & Carr, 2006). Another aspect of the study observed the viability of 
probiotic cells in the yogurt over time. In all tested samples bifidobacteria populations are nearly 
undetectable by the fourth week, leading to the conclusion that consumers should wait no longer 
than three weeks to consume probiotic containing yogurt. Similar results were found in the 
earlier study by Coeuret et al. 2004, in which the quantity of Lactobacillus in probiotic feed and 
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food products was examined (Coeuret, Gueguen, & Vernoux, 2004). Coeuret‘s research found 
that in four of the products that claimed to contain probiotic bacteria the specified strains were 
not detected. Additionally, five products mislabeled the number of bacteria present, and three 
mislabeled the species of lactobacilli present. Investigation of probiotic supplement viability has 
yielded results congruent to the probiotic food counterparts. In 2001 Temmerman et al. tested 30 
dried probiotic supplements and found 11 contained no viable bacteria, 18 contained additional 
species not identified on the label, and only 7contained all species claimed (Temmerman, Pot, 
Huys, & Swings, 2003).  These studies highlight the poor standard of probiotic supplements and 
food products currently available for consumers. This issue is global, ‗similar reports of low 
bacterial counts (zero in some cases), contamination, and unhelpful of misleading labeling of this 
type of product on general sale in the USA (Alcid, Troke, Andszewski, & John, 1994; Gilliland 
& Speck, 1977; Hughes & Hillier, 1990), Austria (Maurer, 1992; Shah, 2000), Italy (Canganella 
et al., 1997; Hoa et al., 2000), and UK (Hamilton-Miller & Shah, 2002; Hamilton-Miller, Shah, 
& Winkler, 1999). 
Without reliable analysis of the microbial ingredients contained in probiotic products 
companies cannot be held accountable for the claims they make on probiotic product labels. 
Consumers are susceptible to mislabeling and consuming products lacking vital desired 
ingredients. Additionally, there is major health concerns when results show products containing 
species of bacteria not claimed on the label. Similar to validating studies conducted to support 
the health benefits of the commonly used bacterial strains, the same accountability should be 
applied to these probiotic food and supplement products. The need for current research is 
apparent.   
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Table 3 
Classification of commercial probiotic supplements available in local stores. 
Classification  Example of Commercial Product  Probiotic strains 
1. Capsule 
1.2 Digestive Advantage   Bacillus coagulansgbi 
1.3 Udo‘s Choice: Adult‘s Probiotic L. casei 
L. rhamnosus 
L. plantarum 
L. acidophilus 
L. bulgaricus  
B. bifidum 
Streptococcus thermophilus  
   1.3 Ultimate Flora 50 Billion  L. acidophilus 
        L. plantarum 
        L. rhamnosus 
        L. salivarius 
        L. bulgaricus 
        L. lactis 
        L. casei 
        B. bifidum 
        B. longum 
        B. breve 
 
2.  Liquid 
   2.1 Probiotic Acidophilus Original   L. acidophilus 
        L. bulgaris 
        L. thermophulis  
2.2 Keybiotics    L. plantarum 
L. rhamnosus 
L. acidophilus 
L. casei 
L. salivarius 
L. bulgaricus 
B. longum 
B. bifidum 
B. lactis 
Streptococcus thermophilus 
2.3 Udo‘s Choice Probiotic (infant)  L. casei 
     L. rhamnosus 
     L. acidophilus 
     B. bifidum 
     B. infantis 
3. Powder 
3.1 Primadophilus Reuteri   L. acidophilus 
     L. rhamnosus 
     L. reuteri  
     L. casei 
     B. infantis 
     B. longum 
3.2 Jarro- Dophilus + FOS   L. rhamnosus 
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     L. acidophilus 
     L. plantarum 
     L. casei 
     B. longum  
     B. lactis 
3.3 Multidophilus Powder   L. acidophilus 
     L. bulgaricus 
     B. bifidum  
4. Tablet 
   4.1 Twinlab: Time Release Probiotics  L. acidophilus 
        L. reuteri 
        L. plantarum 
        L. fermentum 
        B. bifidum 
   4.2 Flora Smart: Advanced Probiotic   L. acidophilus   
        L. rhamnosus 
        L. salivarius 
        L. bulgaricus 
        L. plantarum  
        L. casei  
        B. bifidum 
        B. breve 
        B. longum 
 
   4.3 Life Flora    L. paracasei 
        B. longum 
        Streptococcus thermophilus  
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2.4.1 Required Characteristics for Probiotics in supplements 
 The proven health and wellness benefits of probiotics have sparked rising interest from 
consumers and the food industry within the past several years.  Additional beneficial effects of 
probiotics have been recognized in food preservation, specifically extension of shelf-life and 
enhanced food safety (Gyawali & Ibrahim, 2012; Song et al., 2012). It is important that probiotic 
bacteria possess two main characteristics, stability and functionality, in order to have practical 
applications in probiotic supplements (Figure 3). Stability of probiotics is vital in maintaining a 
high number of viable bacteria during processing and shelf-life. This is referred to as good 
technological properties. Functionality of probiotics is related to their tolerance to low acid and 
bile salts and their antimicrobial, adhesive, and enzyme activity. When incorporating probiotic 
bacteria into supplements, other technological properties to consider are autolytic activity, 
impact on sensory properties, and phage resistance. It is imperative to consider both 
characteristics before selecting potential probiotics for use in supplements. It is equally important 
to note that stability (cell viability) is not always enough to guarantee the probiotic functionality. 
 
Figure 6 Requirement characteristics for probiotics in supplements. 
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5 2.5 Composition of a longevous gut 
In a study conducted in 2010 researchers investigated the gut microflora of centenarians 
of Bama County in the Guangxi Zhuang Autonomous Region in China, famous for the longevity 
of its population.  The 2000 population census in China documented 76 centenarians living in 
Bama County; the ratio was found to be 30.98 compared to the average ratio in Guangxi 
province 4.44 centenarians per 1x 105 people (Zou, 2002). Researchers gathered bacterial species 
from three groups of participants, the first group M  the mean age was 98 years, group S the 
mean age was 70 years, and group C the mean age was 82 years (Zhao et al., 2011).  
Researchers found that the guts of many of the centenarian participants contained larger 
numbers of Bifidobacteria in comparison to the young adults; notable due to elderly populations 
typically possessing fewer Bifidobacteria (Suau et al., 1999).  There were significant age related 
differences in the bacterial species including Clostridium coccoides- Eubacterium rectal, 
Bacteroides-Prevotella, and Clostridium perfringens all of which were found in the longevous 
participants (Zhao et al., 2011). Bacteroides is an important group due to its role in the digestion 
of polysaccharides in the cross-feeding network of the microbiota; they are also able to use an 
array of carbon sources. The high levels of Bacteroides-Prevotella indicate a high level of 
amlolytic activity in the colon of longevous people in Bama.‖ (Zhao et al., 2011) 
6 2.6 Message to the public regarding medication 
―Improving the level of health among older people can—and must—be one of the aims of 
modern gerontology, in order to decrease the rate of hospitalization, the administration of drugs 
and, consequently, the healthcare cost of the ageing population.‖ (Biagi et al., 2012) The 
aspiration of this study is not to deter elderly individuals from taking their medication, but to 
inform them that it is vital to replace the bacteria they lose due to their consumption of the 
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medication. Maintaining a healthy gut is easily achieved through the incorporation of probiotic 
products in the diet.  Probiotics consumed daily will significantly increase the number of good 
bacteria in the gut microbiota. By increasing this microbiota composition positively elderly hosts 
have a larger number of bacteria when consuming medical drugs. Therefore when the drugs do 
disrupt the microbiota there is still a large probiotic population remaining. Individuals 
consuming probiotic products sparingly and inconsistently are not equip with such large numbers 
of good bacteria in the gut. Therefore when the drugs wipe the good bacteria out of the gut 
microflora the individual might suffer from more gastrointestinal issues.  
When searching for probiotic supplements to take consumers should be mindful of the 
labeling of these products. Labels of probiotic supplements should include: notification of the 
presence of live bacteria, the exact nature of the bacteria, identification of species present 
specifically numbers of each species (this should be explained in terms understandable by 
consumers, yet microbiologically accurate), minimum amount of bacteria require to confer 
health effects (either in terms of numbers of bacteria or servings), and accurate content at the 
time of purchase (not simply at some stage of manufacture). Consumers need to inquire about 
probiotic supplements with a specific benefit in mind in order to find an appropriate probiotic to 
cater to that need.  
7 2.7 Justification 
Numerous studies have shown the impact of probiotics on human health, and have 
demonstrated that Bifidobacterium and Lactobacillus strains can positively impact health. It is 
proven that probiotic bacteria are involved in immune modulation and strengthening the gut 
mucosal barrier (Ouwehand et al., 2002). Mechanisms by which these microorganisms 
accomplish this include gut microflora modification, intestinal mucosa adhesion and facilitation 
56 
 
 
of the prevention pathogen attachment or pathogen activation,  modification of dietary proteins 
by the intestinal microflora,  alteration of bacterial enzyme function, and influence of gut 
mucosal permeability(Ouwehand et al., 2002). Probiotics benefit individuals of all ages, and age 
specific probiotic choices are available. The health conferring microorganisms are commercially 
available to consumers in many products including probiotics supplements. These supplements 
come in forms such as capsules, liquids, powders, and tablets. The elderly population is often 
targeted to consume probiotics by the researchers due to the natural decrease of ―good‖ bacteria 
in their gut microbiota with increasing age; as well as the increase incident of elderly taking 
medication.  
Advanced age is typically accompanied by a decrease in health. As health issues arise in 
the elderly population, medications are vital for treatment. Interactions between medications and 
functions of the body have been well studied. There are also many reported adverse effects 
associated with the drugs commonly prescribed to elderly patients; negative impact on the 
gastrointestinal tract physically and alteration of the microbial balance are two of significance. 
The most common adverse effect of non-steroidal anti-inflammatory drugs is damage to the 
mucosa of the gastrointestinal tract (Bjarnason, 2009). Other side effects include gastric pain, 
heartburn, nausea, vomiting, bleeding, perforation, and ulceration (Zeino et al. 2010).  A major 
medication of concern is aspirin, a non-steroidal anti-inflammatory drug or NSAID. NSAID 
drugs are linked to gastric and duodenal damage (Bjarnason & Takeuchi, 2009; Laine, 1996; Soll 
et al., 1991). The more common locations effected by adverse reaction of drugs are the small and 
large intestine, which  represent  20 to 40 percent of drug side effects (Zeino et al., 2010). 
Due to the interaction of medical drugs and functions of the body, there might be a 
similar interaction of medical drugs and naturally occurring probiotic bacteria of the gut 
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microbiota.  There is limited research in this area; therefore with this justification further study 
must be conducted. This project is aimed to study the effect of drugs commonly taken by the 
elderly population, on viability and functionality of probiotics strains found in commercially 
available probiotic supplements. 
8 2.8 Objectives 
The specific aims of this investigation are: 
1) To examine the viability of probiotics in commercial dietary probiotic supplements 
available in local stores. 
2) To determine the impact of aspirin and caffeine on the functionality of a probiotic 
supplement. In this project, functionality was determined by performing: (a) β- galactosidase 
activity, (b) bile resistance, (c) reducing power, and (d) protein expression.  
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9 CHAPTER 3 
Materials and Methods 
3.1 Objective 1 
This objective will examine the viability of probiotics in commercial probiotic 
supplements. 
3.1.1 Materials 
3.1.1.1 Probiotic supplements 
 Ten probiotic supplements were purchased from a local health store in Greensboro North 
Carolina. Each of these supplements claimed to include various strains of bifidobacteria (B. 
longum, B. bifidum, B. lactis, B. breve, B. infantis) and lactobacilli (L. acidophilus, L. 
rhamnosus, L. reuteri, L. gasseri, L. plantarum, L. casei, L. brevis, L. salivarius, L. paracasei) 
(seen in the table below). 
 
 
 
 
 
 
 
 
 
 
 
59 
 
 
Table 4  
Composition of commercial probiotic supplements (by strain). 
 
Supplement Number Commercial Name   Probiotic strains   Form 
1.                        Culturelle    L. GG   Veggie Capsule 
 
2.                        (Natren) Megadophilus    L. acidophilus  Veggie Capsule  
 
3.                        (Solaray) Multidophilus   L. acidophilus  Veggie Capsule 
L. bulgaricus  
B. bifidum 
 
4.                        (Klaire Labs) Ther- biotic Factor 4  B. bifidum  Veggie Capsule 
 
5.                        (Nature‘s Way) Primadophilus Reuteri  L. rhamnosus  Veggie Capsule 
L. acidophilus 
L. reuteri (HA- 188) 
 6.    (Pure Encapsulations) Lactobacillus  L. acidophilus (LA-5) Capsule 
   Acidophilus 
 7.                            (Bluebonnet) Acidophilus Plus FOS  L. acidophilus  Veggie Capsule  
 8.                           (Life Extension) Bifido GI Balance    B. longum (BB536) Veggie Capsule 
 9.                            Kyo- Dolphilus 9   L. gasseri B  Capsule 
       L. gasseri M 
       L. rhamnosus 
       B. bifidum 
       B. longum M 
       B. infantis 
       B. breve 
       B. lactis 
 
 10.                         (Garden of Life) Primal    L. plantarum   Veggie Capsule 
  Defense: HSO Probiotic  L. rhamnosus 
  Formula     L. casei 
       L. brevis 
       L. salivarius 
       L. acidophilus 
       L. paracasei 
       B. lactis 
       B. bifidum 
       B. breve 
       B. longum 
       Bacillus subtilis 
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3.1.1.2 Chemicals and Media 
 Three growth media were used to cultivate the probiotic bacteria listed on the commercial 
supplement labels. MRS agar (deMan, Rogosa& Sharpe) was used for all Lactobacillus and 
Bifidobacterium strains, and was prepared following the manufactures recipe.  Modified BIM 25 
was used for Bifidobacterium strains. The medium contained the following ingredients (gram per 
liter): MRS broth 55; Agar 20; Nalididixic acid 0.02; Polymyxin B sulphate 0.0085; 
Kananycinsulphate 0.05; Iodoacetic acid 0.025; 2,3,5-triphenyltetrazolium chloride 0.025; 
cysteine-hydrochloride 0.5; lithium chloride 1.5; beef extract 1.0; and Tween 20 5mL (S. A. 
IBRAHIM & SALAMEH, 2001). Reinforced Clostridium Agar (RCA) with bromocresol green 
and clindamycin (RCABC) was prepared following the methods of Darukaradhya et al. 2006 
(Darukaradhya, Phillips, & Kailasapathy, 2006). 
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Table 5  
Commercial probiotics supplements and corresponding selective and differential media. 
Supplement Number Probiotic strains   Selective and Differential Media 
1.   L. GG     MRS 
 
2.   L. acidophilus    MRS 
        RCA  
 
3.    L. acidophilus    MRS 
L. bulgaricus     BIM 25 
   B. bifidum    RCA 
 
4.   B. bifidum    MRS 
   B. longum    BIM 25 
   B. lactis 
   B. breve 
 
5.    L. rhamnosus    MRS  
L. acidophilus    RCA  
 
L. reuteri (HA- 188) 
6.     L. acidophilus (LA-5)   RCA 
7.   L. acidophilus    MRS 
   L. bulgaricus    BIM 25 
   B. bifidum    RCA 
   B. longum 
 
8.     B. longum (BB536)   MRS 
        BIM 25 
9.    L. gasseri B    MRS 
L. gasseri M    BIM 25 
L. rhamnosus    RCA 
B. bifidum 
B. longum M 
B. infantis 
B. breve 
B. lactis 
 
10.   L. plantarum     MRS 
L. rhamnosus    BIM 25 
L. casei     RCA 
L. brevis 
L. salivarius 
L. acidophilus 
L. paracasei 
B. lactis 
B. bifidum 
B. breve 
B. longum 
Bacillus subtilis 
 
62 
 
 
3.1.2 Methods 
3.1.2.1 Sample Preparation 
Samples were prepared by adding two capsules of each supplement into individual tubes 
of fresh MRS broth, and then mixed for 15 to 30 s using a vortex. The ten probiotic cultures were 
incubated for 12-14 h at 37°C, for the recovery of the cells. Overnight cultures were then used to 
test for viability and functionality of each probiotic supplement. 
3.1.2.2 Viability of bacterial cells 
Probiotic cultures were serially diluted in 9 ml of sterile 0.1% peptone water, and then 
appropriate dilutions (100 µl) were transferred onto the respective agar. Appropriate dilutions 
were surface plated in duplicate on Lactobacilli MRS (Difco, Detroit, MI, USA) for enumeration 
of Lactobacillus strains. Modified BIM-25 was used for the enumeration of bifidobacteria(S. 
Ibrahim & Carr, 2006). Reinforced Clostridium Agar with bromocresol green and clindamycin 
(RCABC), which is a non-selective media used for the growth of Lactobacillus acidophilus spp., 
and Reinforced Clostridium Agar with aniline blue and dicloxacillin (RCAAD), which is 
differential for Bifidobacterium spp. was also be used (Darukaradhya et al., 2006).  The plates 
will be incubated for 72 h at 37°C. Plates containing 25-250 colonies will be counted to calculate 
bacterial populations. 
3.1.2.3 β- Galactosidase Activity 
          The activity of β-Galactosidase was quantified using the o-nitrophenyl-β-D-galactoside 
(ONPG) assay as described by Miller (J. Miller, 1993).Cultures were first grown to mid log 
phase, and an initial O.D. was measured. The cultures were incubated at 37°C until an O.D. of 
0.7-0.9 (nm) was observed. A 100 µl aliquot of starter culture was washed, and 900 µl of Z 
buffer (composed of 0.06M Na2HPO4; 0.04M NaH2PO4; 0.01M KCl; 0.001M MgSO4*7H2O) 
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was added to the pelleted bacterial cells and washed a second time. Chloroform was then added 
at 10µL per tube and samples were mixed by vortex for 10 s. The mixture was incubated at 37 
°C on a shaker with caps removed for 30 min. After incubation, 200 µl of β-ONPG(4 mg/ml in 
0.1 M phosphate buffer) was added to each tube and vortex in order to start the reaction. The 
reaction was stopped by adding 0.5 mL of 1N Na2CO3 (10.6g/100ml) after the expected yellow 
color had developed.  The time taken for the color to be developed in each tube was recorded.  
Optical density was recorded at OD420 and OD550.  Unit of β-gal produced was calculated as 
follows: 
 Unit of β-gal = 1000 (OD420- 1.75 * OD550)
 
   t * v * OD610nm 
 
Units of β-gal were calculated as described by Miller (S. Ibrahim & O'Sullivan, 2000; J. 
Miller, 1993). 
3.2 Objective 2 
The objective of this investigation was to determine the interaction between one commercial 
probiotic supplement, and commonly administered medical drugs of elderly people. 
Additionally, investigation of the interaction between the supplement and caffeine conducted.  
3.2.1 Population 
The probiotic supplement 5, obtained from the local market will be tested in this 
investigation (Table 4). The supplement was initially be cultured in MRS broth in anaerobic 
culture tubes at 37°C for18 h.  
3.2.2 Determination of β- galactosidase activity 
The activity of β-Galactosidase was quantified using the o-nitrophenyl-β-D-galactoside 
(ONPG) assay as described by Miller (J. Miller, 1993). Cultures were first grown to mid log 
phase, and an initial O.D. was measured. The cultures were incubated at 37°C until an O.D. of 
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0.7-0.9 (nm)was observed. A 100 µl aliquot of starter culture was washed, and 900 µl of Z buffer 
(composed of 0.06M Na2HPO4; 0.04M NaH2PO4; 0.01M KCl; 0.001M MgSO4*7H2O) was 
added to the pelleted bacterial cells and washed a second time. Chloroform was then added at 
10µL per tube and samples were mixed by vortex for 10 seconds. The mixture was incubated at 
37 °C on a shaker with caps removed for 30 minutes. After incubation, 200 µl of β-ONPG (4 
mg/ml in 0.1 M phosphate buffer) was added to each tube and vortex in order to start the 
reaction. The reaction was stopped by adding 0.5 mL of 1N Na2CO3 (10.6g/100ml) after the 
expected yellow color had developed.  The time taken for the color to be developed in each tube 
was recorded.  Optical density was recorded at OD420 and OD550.  Unit of β-gal produced was 
calculated as follows: 
 Unit of β-gal = 1000 (OD420- 1.75 * OD550)
 
   t * v * OD610nm 
 
Units of β-gal were calculated as described by Miller (S. Ibrahim & O'Sullivan, 2000; J. 
Miller, 1993). 
3.2.3 Bile Resistance 
The effects of bile on the growth of LAB cells will be conducted by a method modified 
from those of Gilliand and Walker and Yu and Tsen (Gilliland & Walker, 1990; Yu & Tsen, 
1993). After drug treatment, the surviving LAB cells were collected by centrifugation (7000 rpm, 
5 min) and washed once with PBS (pH 7.2). The cells will be resuspended in 10 ml MRS broth 
with or without 0.3% (w/v) ox gall bile (Sigma; Louisiana, USA) and incubated at 37ºC for 48 h 
under anaerobic conditions. Bile tolerance of the LAB cells was determined by comparing the 
viable LAB counts on MRS agar. Each assayed will also be performed in duplicate (Lin, Hwang, 
Chen, & Tsen, 2006). 
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3.2.4 Reducing Power Assay 
The reducing power of probiotic supplements was determined according to the method 
reported by Mau et al. 2004. Supplement 5 (1.0 ml) was mixed with 2.5 ml sodium phosphate 
buffer (pH = 7.4, 0.02 M) and2.5 ml potassium ferricyanide (1.0%, w/v). This mixture was then 
incubated at 50 °C for 20 min. After, 2.5 ml of trichloroacetic acid (10.0%, w/v) was added to 
the mixture to terminate the reaction. The mixture was centrifuged at 200g for 10 min. The upper 
layer (5 ml) was mixed with 5 ml of deionized water and 1 ml ferric chloride (0.1%, w/v). The 
absorbance was measured at 700 nm. A higher absorbance of the reaction mixture indicates a 
higher reducing power. 
3.2.5 SDS Gel 
Cell extraction procedure was performed as described by Thermo Scientific: B-PER 
Bacterial Protein Extraction Reagent. Bacterial cells were pelleted by centrifugation at 5000 × g 
for 10 min.  B-PER Reagent was added at 4mL per gram of cell pellet. The suspension was 
pipetted up and down until it is homogeneous. When homogeneity was reached the sample was 
incubated for 10-15 min. at room temperature. The lysate was centrifuged at 15,000 × g for 5 
minutes to separate soluble proteins from the insoluble proteins.  
BCA was performed as described by Thermo Scientific: Pierce BCA Protein Assay Kit.  
First standards and working reagent were prepared. Diluted Albumin (BSA) Standards were 
prepared using the table provided by Thermo Scientific. The contents of one Albumin Standard 
(BSA) were diluted into several clean vials, preferably using the same diluent as the sample(s). 
Each 1mL ampule of 2mg/mL Albumin Standard is sufficient to prepare a set of diluted 
standards for either working range suggested in the table. There will be sufficient volume for 
three replications of each diluted standard. The BCA Working Reagent (WR) required the use of 
the following formula to determine the total volume of WR required. 
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(# standards + # unknowns) × (# replicates) × (volume of WR per sample) = total volume WR required.  
Once the standards and working reagent were prepared 0.1mL of each standard and 
unknown sample replicate was pipetted into an appropriately labeled test tube. WR (2 mL) was 
added to each tube and was mixed by vortex. Tubes were incubated at 37°C for 30 minutes.  
With the spectrophotometer set to 562nm, the instrument was zeroed using a curette filled only 
with water. The absorbances of all the samples were measured within 10 minutes.  
 The average 562nm absorbance measurement was subtracted from the blank standard replicates 
from the 562nm absorbance measurement of all other individual standard and unknown sample 
replicates. A standard curve was prepared by plotting the average blank-corrected 562nm 
measurement for each BSA standard vs. its concentration in µg/mL. This standard curve was 
used to determine the protein concentration of each unknown sample. 
 SDS Page. The polyacrylamide gel was prepared according to standard protocol. Samples 
were loaded, and the gel was run at 25 mA in 1x SDS Running Buffer. The gel was then stained 
and placed in a plastic container. The gel was then covered with isopropanol fixing solution and 
shaken at room temperature. For 0.75 mm-thick gels, shake 10 to 15 min; for 1.5 mm thick gels, 
shake 30 to 60 min. After appropriate shaking time the fixing solution was poured off. The gel 
was then covered with staining solution and shaken at room temperature for 2 hours. The 
staining solution was poured off and the gel was washed with 10% acetic acid.  
10  
 
11  
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12 CHAPTER 4 
Results 
4.1 Objective 1 
In this study we used commercial probiotic supplements available in the market to 
determine the viability of bacterial cells. These supplements were divided into three groups 
based on the type of bacterial population (Lactobacillus spp., L. acidophilus, Bifidobacterium 
spp.).  Table 6 shows the initial population of probiotic cultures found in ten commercial dietary 
supplements. The initial bacterial populations of group 1, Lactobacillus spp., ranged from 5.39 to 
9.39 log CFU/ml. Supplement 8 exhibited the lowest number at 5.39 ± 0.00 log CFU/ml. 
Supplement 1 exhibited the highest number at 9.39 ± 0.00 log CFU/ml. The initial bacterial 
populations of group 2, L. acidophilus, ranged from 5.63 to 8.81 log CFU/ml. Supplement 10 
exhibited the lowest number at 5.63 ± 0.21 log CFU/ml. Supplement 2 exhibited the highest 
number at 8.81 ± 0.06 log CFU/ml. In group 3, Bifidobacterium spp., the initial bacterial 
populations ranged from 4.38 to 7.86 log CFU/ml. Supplement 8 exhibited the lowest number at 
4.38 ± 0.00 log CFU/ml. Supplement 9 exhibited the highest number at 7.86 log CFU/ml.  The 
initial population count indicates the presence of probiotic bacteria in all tested supplements as 
claimed on the label. 
Table 6 also shows the changes in the viability of bacterial cells present in the 
supplements after 4 weeks in refrigeration storage (4°C). Viability post storage period in group 1 
ranged from 5.27 to 9.10 log CFU/ml. Supplement 10 exhibited the lowest presence at 5.27 
±0.14 log CFU/ml, whereas supplement 1 exhibited the highest presence at 9.10 ± 0.04 log 
CFU/ml. Viability post storage period in group 2 ranged from 4.34 to 7.89 log CFU/ml. 
Supplement 10 exhibited the lowest number at 4.34 ± 0.16 log CFU/ml, and supplement 9 
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exhibited the highest number at 7.89 ± 0.26 log CFU/ml. viability post storage period in group 3 
ranged from 4.08 to 7.55 log CFU/ml.  Supplement 10 exhibited the lowest population count at 
4.08 ± 0.09 log CFU/ml. Supplement 9 exhibited the highest population count at 7.55 ± 0.19.  
A comparison of viability pre- and post storage period reveals a reduction in bacterial 
population count. The maximum reduction in group 1 was found to be 3 log CFU/ml 
(Supplement 6), followed by 1 log CFU/ml (Supplement 2, 7, 10). All other supplements 
exhibited reductions ≤ 1 log CFU/ml (Supplements 3 and 9). The maximum reduction in group 2 
was found to be 2 log CFU/ml (Supplement 6), followed by 1 log CFU/ml (Supplement 2). All 
other supplements exhibited reductions ≤ 1 log CFU/ml (Supplements 1, 3, 5, 7, 9, and 10).The 
maximum reduction in group 3 was found to be ≤ 1 log CFU/ml (Supplements 5, 7, 9, and 10). 
One supplement, however, did demonstrate ≤1 log CFU/ml increase (Supplement 3). 
A few supplements were able to maintain their initial population count after the storage 
period (Supplements 1, 4, 5, 78, and 10).  Post storage viability indicates an increased likelihood 
of supplement capability to exert health-promoting effects as claimed on the label, up to human 
consumption. Supplements 1, 5, and 7 each exhibited population counts that are maintained and 
met the required 8 log CFU/mL minimum. Supplements 4, 8 and 10, however, maintained their 
initial population count but do not meet the suggested minimum 8 log CFU/mL of 
microorganisms required to confer positive health effects. Based on the label description 
supplements 4, and 8 should contain 10+ and 2 billion CFUs respectively. Supplement 10 did not 
claim a CFU amount on the label. This large number of functional bacteria present during 
consumption ensures a sufficient amount of the probiotic microorganisms reach the large 
intestine. 
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Table 6  
Bacterial population in different types of supplements during refrigeration storage (4° C) for 4 
weeks. 
 
4.1.2 β- Galactosidase (β-gal) Activity 
Table 4.2 shows the β –gal activity of the ten commercial probiotic supplements both in 
the presence of glucose (uninduced) and lactose (induced). The mechanism of this color change 
can be seen in Figure 4.1 below. It involves the breakdown of ONPG (colorless) into galactose 
(colorless) and o-Nitrophenol (yellow). The bright yellow color signifies the breakdown of 
lactose; increasing intensity of the yellow color indicates increasing β-gal activity (Figures 4.2 
and 4.3). The activity of β-gal in the uninduced group, control, ranged between 26and 860 Miller 
unit/mL, and activity in the induced group ranged from 160to 1,120 Miller unit/mL. The average 
β- gal activity of the control samples was 170 Miller units.  The induction of probiotic 
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supplements with lactose increased the average β- gal activity. Lactose acted as a carbohydrate 
source on the induction of β-gal activity. Notable increases from uninduced to induced enzyme 
activity include: Supplement 5, 50 to 1,120 Miller units; Supplement 6, 28 to 1,068 Miller units; 
and Supplement 8, 26 to 1,065 Miller units. Two supplements exhibited minor increases, but 
maintained relatively high β-gal activity levels. Supplement 3, 860 to 885 Miller units; and 
Supplement 4, 700 to 715 Miller units.  Supplements 5 exhibited the strongest enzyme activity at 
1,120 Miller units. Supplement 10 exhibited the lowest enzyme activity at 1.45 Miller units. 
Supplements exhibiting the lowest enzyme activity and lowest increase from uninduced to 
induced include: Supplement 1, 0.80 to 15 Miller units; Supplement 7, 12 to 160 Miller units; 
and Supplement 10, 0 to 1.45 Miller units. 
 
Figure 7 Mechanism of β-galactosidase. 
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Table 7 
β -galactosidase activity in commercial probiotic supplements. 
 
β- Galactosidase activity (Miller units) 
 
Supplements   Uninduced    Induced  
 
Supplement 1   0     15    
Supplement 2   0     775     
Supplement 3   860     885     
Supplement 4   700     715    
Supplement 5   50     1,120     
Supplement 6   28     1,068     
Supplement 7   12     160     
Supplement 8   26     1,065     
Supplement 9   5     6     
Supplement 10  0     1    
   
 
 
Figure 8 (left) β -gal activity in the presence of glucose (uninduced). (right) β -gal activity in the 
presence of lactose (induced). 
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4.2 Objective 2 
Since Supplement 5 demonstrated viability and maintained viability during refrigerated 
storage, it was chosen for additional experiments in objective 2. In this objective we attempt to 
understand the impact of aspirin and caffeine on the functionality of a probiotic supplement. In 
this project, functionality was determined by performing: (a) β- galactosidase activity, (b) bile 
resistance, (c) reducing power, and (d) protein expression. 
4.2.1 Exposure to aspirin and caffeine 
In the experiment an aspirin stock composed of 1 gram of aspirin and 10 mL of Dimethyl 
sulfoxide (DMSO) was prepared to determine the impact of aspirin on the supplement. After a 12 
h growth period at 37°C the supplement was serially diluted in 9 mL of peptone water. Then 
100µl of aspirin stock was added to each dilution and incubated for 2 h at 37°C. The exposure of 
Supplement 5 to aspirin resulted in a population decrease from 8.95±0.14 to 2.20±3.10 log 
CFU/mL. When bacterial cells exposed to caffeine there was a slight decrease to 8.72±0.04 log 
CFU/mL. 
4.2.2 β- galactosidase (β- gal) activity 
The effect of aspirin and caffeine on the β-gal activity of a probiotic supplement 
(Supplement 5) was determined. The levels of β-gal activity varied dependent on the exposure to 
caffeine or aspirin. After 2 h of incubation, enzyme activity of supplement 5 can be seen in Table 
4.3 Supplement 5 exhibited an increase to 1090 Miller units compared to the control at 500 
Miller units after being exposed to caffeine. Supplement 5 treated with aspirin showed a 
significant decrease in activity, declining to 62 Miller units.  
Additionally, we determined the effect of aspirin on supplement 5 at progressively lower 
inoculums. The initial β-gal was 697.5 Miller units, while the first inoculum level demonstrated 
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an increase to 1629.5 Miller units, each subsequent dilution factor decreased in enzyme activity. 
These results are consistent with research that stresses the importance of probiotic consumption 
in order to replenish or sustain the level of beneficial bacteria in the microbiota. The higher 
inoculum levels did not exhibit significant enzyme activity decreases after exposure to aspirin 
compared to lower inoculum levels which demonstrated weaker enzyme activity post aspirin 
exposure.  
The increase of β-galactosidase after exposure of caffeine can be contributed to the 
hydrolysis of the cell membrane by caffeine. Caffeine allows the enzyme to be released in the 
media, whereas aspirin inhibits protein synthesis.  
 
Table 8  
(a) Supplement β- gal activity post aspirin and caffeine exposure. (b) β – gal activity in 
decreasing inoculum levels.  
 
(a) β- Galactosidase activity (Miller units) 
 
Treatment   Uninduced     Induced     
 
Control   100 ± 84    500 ± 42   
Caffeine   162 ± 32    1090 ± 287   
Aspirin   51 ± 18    62 ± 79   
  
(b) β-Galactosidase activity in decreasing inoculum levels (Miller units) 
Dilution Factor  Uninduced     Induced    
Control   162.5     697.5     
-1    200     1629.5     
-2    87.5     319.5     
-3    6     190.5    
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Figure 9 (left) β- gal activity after exposure to aspirin and (right) after exposure to caffeine. 
 
Table 9  
β-gal activity post exposure to 3% bile.  
 
β- Galactosidase activity (Miller units) 
 
Treatment   Induced     Uninduced 
 
Control   486 ± 122    52 ± 60 
Bile    780 ± 290    327 ± 10 
 
We also evaluated the effect of bile (3% w/v) on the β-gal activity of supplement 5. An 
incubation period of 2 h resulted in an increase of supplement enzyme activity as seen in Table 
4.4. Supplement 5 exhibited an increase to 780 Miller units compared to the control at 486 Miller 
units after being exposed to bile (3% w/v). Similar studies of the effect of bile on β-gal activity 
also found the activity to be greater if bile was included in the medium. Zarate et al. 2000 
observed the β-gal activity enhancement of P. acidipropionici  in the presence of bile salts due to 
the permeabilization of the cells during the first hour of exposure (Zárate, Chaia, González, & 
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Oliver, 2000). These effects have also been demonstrated in lactobacilli species (De Valdez et 
al., 1997; Noh & Gilliland, 1993).  
 
 
Figure 10 β-gal activity after exposure to bile (3%). 
 
4.2.3 Bile resistance 
The survival of Supplement 5 in the presence of bile (3% w/v) was determined. The 
initial population was 9.14 ± 0.09 log CFU/mL. Post exposure the population slightly decreased 
to 8.99 ± 0.04 log CFU/mL. 
Following survival, bile resistance was investigated. After drug treatment, the surviving 
LAB cells from supplement 5 were resuspended in 9 mL MRS broth with or without 3% (w/v) 
bile. Table 4.5 shows the bile resistance of the probiotic supplement after exposure to aspirin. 
The decreasing dilution factors represent the decrease in bacteria population in the presence of 
consistent amounts of aspirin (100 µl). Resistance to bile is an important property for probiotic 
strains.  
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Table 10  
Bile resistance of probiotic supplement after exposure to aspirin. 
 
Bile Resistance (log CFU/mL) 
 
    Bile (3% w/v) Exposure   No Bile Exposure 
 
Control   7.88 ± 0.26     7.98 ± 0.55 
Treatment (aspirin)  5.63 ± 0.15     5.48 ± 0.28 
 
4.2.4 Reducing power 
Antioxidant properties were assayed in terms of antioxidant activity (AOA) by reducing power. 
The behavior of strains found in Supplement 5 in was determined by measuring changes in the 
absorbance at 700 nm for cultures exposed to caffeine and aspirin. The reducing power of 
supplement 5 was 0.39.  
 
Figure 11 Reducing power to probiotic supplement. (Left: blank; right: supplement) 
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            4.2.5 Protein expression 
The effect of aspirin and caffeine on the protein expression of supplement 5 was 
examined.  First protein concentration was established. Protein concentration detects total 
protein. Figure 12 shows protein concentration of supplement 5. There was a decrease in protein 
concentration from 836.21 µg/ml (control) to 547.59 µg/ml after exposure to aspirin. Similarly, 
when the supplement was exposed to caffeine, protein concentration decreased from 
836.21µg/ml (control) to 652.13 µg/ml.  
 
Figure 12 Protein concentration of supplement exposed to aspirin and caffeine. 
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Figure 13 Protein expression (Silver stain) 
 
The result of total protein was confirmed with a gel. From left to right, Figure 13 shows lanes 
containing the 1) marker, 2) control cells, 3) aspirin treated cells, 4) caffeine treated cells, 5) 
control supernant, 6) aspirin treated supernant, 7) caffeine treated supernant, 8) control mix, 9) 
aspirin treated mix, and 10) caffeine treated mix. For explanatory purposes, these samples were 
grouped into 3 categories. Samples 2 to 4 were grouped as I, characterized by the protein source 
being the pelleted bacterial cells. Samples 5 to 7 were grouped as II, characterized by the protein 
source being the supernant. Samples 8 to 10 were grouped as III, characterized by the protein 
source being a mixture of the supernant and pelleted cells.   
1 2 3 4 5 6 7        8          9        10 
250— 
150— 
100— 
25 — 
 
20 — 
15 — 
10 — 
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Protein expression of Supplement 5 (Figure 13), was markedly affected when treated with 
aspirin in comparison to treatment with caffeine and the control. Aspirin was found to inhibit 
individual proteins. Observations indicate that in group I, 9 groups are present in sample 2, 7 
groups are present in sample 3, and 8 groups are present in sample 4. In group I the lower profile 
is absent in both aspirin and caffeine treatments. Group III shows 6 groups are present in the 
sample 8, 3 groups are present in sample 9, and 3 groups are present in sample 10. The number 
of observable bands was lower than in untreated samples.  
In terms of observable total bands as individuals from group I, sample 2 has 15 bands, 
sample 3 has 8 bands, and sample 4 has 10 bands. From group III, sample 8 has 6 bands, sample 
9 has 3 bands, and sample 10 has 3 observable total bands.  
The molecular weight of the probiotic bacteria are lower than 250 kD, which was to be 
expected. The effect of aspirin and caffeine were different; aspirin had effect on the lower bands 
and caffeine affected the lowest band the most. Proteins were only detected in samples 
containing cells; it was these proteins that treatment affected. The supernant demonstrated no 
protein presence.  
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13 CHAPTER 5 
Discussion and Future Research 
 
In this project, we have two objectives which were to determine: (a) the viability of 
probiotics in commercial probiotic supplements in laboratory medium by surface plating and 
measuring β- galactosidase activity, and (b) the interaction between probiotic supplements and 
commonly administered medical drugs of elderly people, and commonly consumed caffeine. 
The first experiment of Objective 1, we determined bacterial populations by counting 
CFU/ml after 24 hr incubation at 37°C.  Ten commercial dietary supplements were surface 
plated on selective and/or differential media based on their probiotic content. Viability was 
demonstrated via presence upon surface plating on respective media, thus confirming the 
presence of bacterial populations claimed on the supplement labels. Declines in population were 
observed in a few supplements after the storage period of four weeks. Our results indicate that 
storage, even as directed by labels, impacts the viability of probiotics in commercial dietary 
supplements. Ibrahim and Carr (2006) reported, similarly, that probiotic cultures in commercial 
yogurt brands were not viable after 3-4 weeks of storage at 4°C.Increasing knowledge on the 
effects storage has on probiotic products is a crucial aspect of ensuring health benefits are 
conferred. Functionality and health benefits of probiotic supplements may vary widely.  
The second experiment of Objective 1 measured β-gal activity of the supplements.  This 
enzyme activity is important in the breakdown of lactose, the main sugar in milk. Milk contains 
4.8% lactose (Chandan, 1997). Many humans suffer from lactose intolerance, the inability to 
digest lactose into its constituents, glucose and galactose, due to low levels of lactase enzyme in 
the brush border of the duodenum (Rusynyk & Still, 2001). When undigested lactose remains in 
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the gut of a lactose intolerant individual a range of symptoms can arise. These symptoms 
typically occur within two hours of lactose ingestion and include abdominal pain, bloating, 
borborygmi (stomach growling), diarrhea, nausea, and vomiting (van Griethuysen-Dilber, 
Flaschel, & Renken, 1988).  β–gal catalyzes the hydrolysis of lactose by breaking the β 1–4 
linkage between glucose and galactose. Lactose is believed to  trigger β- galactosidase activity 
by the lac operon mechanism (Reznikoff & Miller, 1980). 
Our results were consistent with previous studies in which the presence of lactose in 
media enhanced β-gal activity when compared to the presence of glucose. Akolkar et al.  (2005) 
and Hsu et al. (2005) found that the presence of lactose in the media led to β-gal activity 
enhancement for bifidobacteria and L. acidophilus specifically, which also supports the results 
found in our study. We also examined the effect of bile on β–gal activity and found an increase 
in enzyme activity when bile was included in the medium. This finding is consistent with that of 
Zarate et al. 2000 who contributed this enzyme activity enhancement to the permeabilization of 
probiotic strains by bile. This allowed more substrate to enter the cells to be hydrolyzed by β–
galactosidase (Zárate et al., 2000).  
Overall lactose intolerant individuals can be well treated by dietary modification and 
education one properly diagnosed with the condition (S. A. Ibrahim & Gyawali, 2013). Milk and 
other dairy products can remain in the diet of lactose maldigesters without them experiencing 
symptoms through this dietary modification. The addition of probiotics like supplement 5 could 
be an effective means of alleviating lactose intolerance.  
Objective 2 was conducted using supplement 5 which demonstrated a high viability and 
maintained viability during refrigerated storage during Objective 1. In this objective we 
attempted to understand the impact of aspirin and caffeine on the functionality of a probiotic 
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supplement; functionality was determined by performing: (a) β- galactosidase activity, (b) bile 
resistance, (c) reducing power, and (d) protein expression. The first experiment of the second 
objective determined the impact of aspirin and caffeine exposure on the supplement. We used 
both caffeine and aspirin due to caffeine‘s use as an adjuvant to the analgesic actions of aspirin 
and paracetamol, and because of the high consumption of caffeine containing products such as 
coffee and tea (Gokulakrishnan et al. 2004). Caffeine is a purine alkaloid which acts as a central 
nervous system stimulant and also has negative withdrawal effects (Gokulakrishnan et al. 2004).  
Coffee and tea plants are the major sources of natural caffeine.  Average consumption of caffeine 
in humans ranges from 80-400 mg/ (person day) (Gokulakrishnan et al. 2004). 
Exposure to aspirin was found to decrease bacterial population approximately 6.75 log 
CFU/ml, and exposure to caffeine decreased population approximately 0.23 log CFU/ml. Our 
results are supported by research that has also demonstrated the negative impact of aspirin on 
survival rate of probiotic bacteria. Thus indicating the possible negative role of aspirin, in certain 
doses, on the microbiota. 
The second experiment of Objective 2 determined the effect of aspirin and caffeine on the 
β-gal activity of supplement 5.  Aspirin exposure caused a decrease in enzyme activity while 
caffeine caused a significant increase. This increase in enzyme activity is believed to be 
contributed to caffeine hydrolyzing the cell membrane, allowing for the nutritive media to enter 
the cell.  
The third experiment of Objective 2 investigated the survival of supplement 5 in the 
presence of bile (3% w/v) and bile resistance. Supplement 5 demonstrated the ability to survive 
in the presence of bile by exhibiting a slight decrease to 8.99 ± 0.04 from 9.14 ± 0.09 the control. 
The survival of supplement 5 meets the criteria for probiotic bacteria.  
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The fourth experiment of Objective 2 examined the reducing power of supplement 5. 
Reducing power is often used to evaluate the ability of an antioxidant to donate an electron. 
Although the reducing power of supplement 5 was found to be relatively low, the supplement 
does prove to have some antioxidant properties.  
The fifth experiment of Objective 2 determined the protein expression of supplement 5. 
We found BPER useful for lysing bacteria, specifically probiotic bacteria. Our BCA results 
showed that treatment, with caffeine and aspirin, reduced the total protein concentration of 
bacteria. SDS Page using silver stain detected major protein bands. Treatment changed the 
number and intensity of low molecular bands. There were unique target proteins affected by 
caffeine and aspirin respectively.  Overall, treatment with caffeine and aspirin both affected 
concentration of the target protein.  
In conclusion, during the protein expression experiment we identified a useful approach 
using BPER and SDS Page (12% gel and silver stain) to evaluate probiotic quality that can 
impact efficacy. Upon completion of the SDS page researchers concluded that the use of 12% 
gels successful, and in terms of staining the gel a Silver stain was a better approach than the 
Coomassie stain due to its sensitivity for detection of bacterial proteins. The results of both 
the Silver and Coomassie stains can be found above (figures 13 and 14 respectively). Both stains 
were allowed to set overnight.  
Overall, the BCA (total protein), cell counts, and protein profile corroborate each other. 
The protein profile indicates distinct proteins may be the target of aspirin and caffeine. The 
prominent bands ~75-37 kD are not as susceptible as the lower weight band. Future studies could 
investigate and identify these proteins and find what factors make them resistant to the effects of 
aspirin and caffeine. In addition to affecting the viability of bacteria, treatment also affects the 
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concentration and type of protein in probiotic bacteria. Further studies on the significance of 
these proteins in probiotic health promoting functions are needed.  
Table 5.1 provides a list of additional ingredients found in the probiotic supplements 
investigated during this study. Many of these ingredients possess prebiotic properties that are 
believed to boost the health promoting attributes of the probiotic cultures in the supplements. A 
predominant ingredient in the dietary supplements is inulin (chicory root extract). This soluble 
dietary fiber is not digested or absorbed in the stomach. Inulin passes through to the large 
intestine where it ferments and is used by the microbiota as a fuel source. Ingredient content 
could have an effect on the β- gal activity in the supplements. 
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Table 11 
 β-gal activity of probiotic supplements (Miller units) and additional ingredients (excluding 
probiotic strains). 
 
Supplements  Induced  Uninduced  Ingredients  
  
Supplement 1  15  0  Inulin (chicory root extract) 
Hypromellose 
Vegetable magnesium stearate 
 Silica 
Titanium dioxide (color) 
 
Supplement 2  775  0  Vitamin C 
Cellulose powder 
Dehydrated potato powder 
Organic garbanzo bean (chick-pea) extract 
Vegetable capsule (hypromellose) 
L-leucine. 
 
Supplement 3  885  860  Vegetable cellulose capsule 
Cellulose 
Stearic acid 
Magnesium stearate 
Maltodextrin 
 
Supplement 4  715  700  Inulin (derived from chicory root) 
Vegetarian capsule (hydroxypropylmethl-cellulose, 
water) 
InTactic proprietary polysaccharide complex 
L-leucine 
 
Supplement 5  1,120  50  Vitamin C (ascorbic acid) 
NutraFlorascFOS (short-chain 
fructooligosaccharides) 
Plant-derived capsule 
Aqueous enteric-coating (modified cellulose, sodium 
alginate, stearic acid, fractionate [non-hydrogenated] 
coconut oil, Oleic acid) 
 
Magnesium stearate 
Supplement 6  1,070  28  Rice starch 
Vegetarian capsule (cellulose, water) 
 
Supplement 7  160  12  FOS (fructooligosaccharides) 
Kosher vegetable capsules 
Vegetable cellulose 
Vegetable magnesium stearate 
 
Supplement 8  1,065  26  Microcrystalline cellulose 
Vegetable cellulose 
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Tapioca starch 
Ascorbylpalmitate 
Silica  
 
Supplement 9  6  5  Gelatin 
       Starch (potato, tapioca and corn) 
       Silica 
 
Supplement 10  1.45  0  Calcium carbonate 
       Sodium croscarmellose 
       Silica 
       Magnesium stearate (vegetable source) 
       Rice maltodextrin 
       Vegetable coating 
       Bacterial proteases 
 
 
 
Based on the results of this study we found that storage of probiotic supplements effects 
viability and believe that there is a need to address increasing the knowledge on the effects of 
storage on probiotic products to ensure health benefits are conferred to consumers. We also 
found that aspirin can reduce the bacterial population of probiotic supplements. However recent 
studies have found that the dosage of 81 mg of aspirin may not decrease the microbiota 
population, but change it. Future work should be directed toward the dosage of aspirin and the 
functionality of the microbiota in order to understand how these two components may work 
together in promoting heart health. The change in the functionality of the microflora could be a 
key element in how the microbiota and aspirin work together in heart attack prevention.  
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